[
  {
    "page_num": 1,
    "page_width": 595.276,
    "page_height": 790.866,
    "ordered_elements": [
      {
        "type": "title",
        "bbox": [
          34.747816772460936,
          387.051240234375,
          98.867109375,
          398.17248046875
        ],
        "confidence": 0.9984456896781921,
        "original_box": {
          "type": "Title",
          "bbox": [
            34.747816772460936,
            387.051240234375,
            98.867109375,
            398.17248046875
          ],
          "confidence": 0.9984456896781921
        },
        "center_x": 66.80746307373047,
        "center_y": 392.6118603515625,
        "reading_order": 1,
        "content": "INTRODUCTION"
      },
      {
        "type": "text",
        "bbox": [
          34.28806915283203,
          608.8109326171875,
          287.18578125,
          701.300390625
        ],
        "confidence": 0.9943521022796631,
        "original_box": {
          "type": "Text",
          "bbox": [
            34.28806915283203,
            608.8109326171875,
            287.18578125,
            701.300390625
          ],
          "confidence": 0.9943521022796631
        },
        "center_x": 160.736925201416,
        "center_y": 655.0556616210938,
        "reading_order": 2,
        "content": "Haemagglutinin(HA)istheprimaryantigenintheinductionof\na protective immune response against the influenza virus, and\nthus a key vaccine target. Expressed as trimeric glycoproteins on\ntheviralsurface,HAbindstosialicacidontargetcellstofacilitate\nhostcellentryandmediatesthefusionoftheviralenvelopetothe\nlateendosomalmembrane. Neutralisingantibodiesthatblock HA\neffectively prevent viral entry into target cells and have been\nshowntoprotectthehostfrominfection10,11.Anotherviralsurface\nprotein, neuraminidase (NA), cleaves sialic acid and releases"
      },
      {
        "type": "text",
        "bbox": [
          35.3551821899414,
          507.0873779296875,
          282.6301904296875,
          608.325380859375
        ],
        "confidence": 0.992618978023529,
        "original_box": {
          "type": "Text",
          "bbox": [
            35.3551821899414,
            507.0873779296875,
            282.6301904296875,
            608.325380859375
          ],
          "confidence": 0.992618978023529
        },
        "center_x": 158.99268630981445,
        "center_y": 557.7063793945313,
        "reading_order": 3,
        "content": "Influenza Asubtypes H1N1and H3N2, andinfluenza Blineages\nB/Yamagata and B/Victoria circulate routinely in humans and are\nincludedinseasonalinfluenzavaccines 8. Influenza Asubtypescan\nalsogiverisetohighlypathogenicvirusesthroughcross-overfrom\nanimal reservoirs to humans9. In the past century, four novel\ninfluenza Avirusstrainshaveemergedinthisway, eachleadingto\na global pandemic (H1N1 in 1918; H2N2 in 1957; H3N2 in 1968;\nand H1N1in 2009). Vaccinesagainstsuchstrainsarepreparedand\nstockpiled as government initiatives for emergency use in\npotential future pandemics."
      },
      {
        "type": "text",
        "bbox": [
          35.05644470214843,
          397.727841796875,
          284.17403320312496,
          509.0659716796875
        ],
        "confidence": 0.9939171671867371,
        "original_box": {
          "type": "Text",
          "bbox": [
            35.05644470214843,
            397.727841796875,
            284.17403320312496,
            509.0659716796875
          ],
          "confidence": 0.9939171671867371
        },
        "center_x": 159.6152389526367,
        "center_y": 453.39690673828125,
        "reading_order": 4,
        "content": "Seasonal influenza is responsible for 290,000\u2013650,000 deaths per\nyear due to respiratory diseases alone and 3\u20135 million cases of\nsevereillnessworldwide 1\u20133. Inthe USA, influenzawasthoughtto\naccount for 52.7 hospitalisations per 100,000 people during the\n2019\u20132020 season. These numbers are significantly higher in\nyoungchildrenandadultsaged65andolder1,2,4.Extra-pulmonary\ncomplications of influenza infection constitute a further under-\nrecogniseddiseaseburden4,5.Overall,suchahighdiseaseburden\ncarries substantial social and economic cost6,7. Prevention of\nseasonal influenza epidemics, as well as preparedness for future\npandemics,is thusaglobal priority."
      },
      {
        "type": "text",
        "bbox": [
          33.21237854003906,
          151.59834228515624,
          273.558427734375,
          162.66554077148436
        ],
        "confidence": 0.9735447764396667,
        "original_box": {
          "type": "Text",
          "bbox": [
            33.21237854003906,
            151.59834228515624,
            273.558427734375,
            162.66554077148436
          ],
          "confidence": 0.9735447764396667
        },
        "center_x": 153.38540313720705,
        "center_y": 157.13194152832028,
        "reading_order": 5,
        "content": "Arun B. Arunachalam 1 , Penny Post 2and Deborah Rudin 3"
      },
      {
        "type": "text",
        "bbox": [
          51.047336425781246,
          339.83958251953123,
          309.52997314453125,
          349.8869311523437
        ],
        "confidence": 0.7284221053123474,
        "original_box": {
          "type": "Text",
          "bbox": [
            51.047336425781246,
            339.83958251953123,
            309.52997314453125,
            349.8869311523437
          ],
          "confidence": 0.7284221053123474
        },
        "center_x": 180.28865478515624,
        "center_y": 344.8632568359375,
        "reading_order": 6,
        "content": "pj Vaccines (2021) 6:144 ; https://doi. org/10.1038/s 41541-021-00403-"
      },
      {
        "type": "text",
        "bbox": [
          36.63035980224609,
          717.5759326171875,
          546.9064453125,
          736.25291015625
        ],
        "confidence": 0.985614001750946,
        "original_box": {
          "type": "Text",
          "bbox": [
            36.63035980224609,
            717.5759326171875,
            546.9064453125,
            736.25291015625
          ],
          "confidence": 0.985614001750946
        },
        "center_x": 291.768402557373,
        "center_y": 726.9144213867187,
        "reading_order": 7,
        "content": "1Analytical Sciences, R&DSanofi Pasteur,1Discovery Drive, Swiftwater, PA18370, USA.2Regulatory Affairs, Protein Sciences, a Sanofi Company,1000Research Parkway, Meriden\nCT06450, USA.3Global Medical Affairs, Sanofi Pasteur,1Discovery Drive, Swiftwater, PA18370, USA. \u2709 email: Arun. Arunachalam@sanofi. com"
      },
      {
        "type": "text",
        "bbox": [
          41.327347412109376,
          252.33150146484374,
          533.1979248046874,
          328.690810546875
        ],
        "confidence": 0.957181453704834,
        "original_box": {
          "type": "Text",
          "bbox": [
            41.327347412109376,
            252.33150146484374,
            533.1979248046874,
            328.690810546875
          ],
          "confidence": 0.957181453704834
        },
        "center_x": 287.2626361083984,
        "center_y": 290.5111560058594,
        "reading_order": 8,
        "content": "structuralfeatures. Theabsenceofprotease-drivencleavageandadditionofsimple N-linkedglycanshelptopreserveandexpos\ncertainconservedepitopeson HAmolecules, whicharelikelyresponsibleforthehighlevelsofbroadlycross-reactiveandprotectiv\nantibodieswithrarespecificitiesobservedwith RIV4. Furthermore, thepresenceofuniformcompact HAoligomersandabsence\neggproteins, viral RNAorprocessimpurities, typicallyfoundinconventionalvaccines, areexpectedtoeliminatepotentialadvers\nreactionstothesecomponentsinsusceptibleindividualswiththeuseof RIV4. Thesedistinctstructuralfeaturesandpurityofth\nrecombinant HAvaccinethusprovideanumberofbenefitsinvaccineperformancewhichcanbeextendedtootherviraltarget"
      },
      {
        "type": "list",
        "bbox": [
          43.425208740234375,
          182.0454345703125,
          545.8387060546875,
          340.00048828125
        ],
        "confidence": 0.5506378412246704,
        "original_box": {
          "type": "List",
          "bbox": [
            43.425208740234375,
            182.0454345703125,
            545.8387060546875,
            340.00048828125
          ],
          "confidence": 0.5506378412246704
        },
        "center_x": 294.6319573974609,
        "center_y": 261.02296142578126,
        "reading_order": 9,
        "content": "Theinfluenzavaccinefieldhasbeenconstantlyevolvingtoimprovethespeed,scalability,andflexibilityofmanufacturing,andto\nimprovethebreadthandlongevityoftheprotectiveimmuneresponseacrossagegroups,givingrisetoanarrayofnextgeneration\nvaccinesindevelopment.Amongthese,therecombinantinfluenzavaccinetetravalent(RIV4),usingabaculovirusexpressionvector\nsystemtoexpressrecombinanthaemagglutinin(r HA)ininsectcells, istheonlyonetohavereachedthemarketandhasbeen\nstudiedextensively. Wedescribehowtheuniquestructuralfeaturesofr HAin RIV4improveprotectiveimmuneresponsescompared\ntoconventionalinfluenzavaccinesmadefrompropagatedinfluenzavirus.Inadditiontothesequenceintegrity,characteristicof\nrecombinantproteins, uniquepost-translationalprocessingofther HAininsectcellsinstillsfavourabletertiaryandquaternary\nstructuralfeatures. Theabsenceofprotease-drivencleavageandadditionofsimple N-linkedglycanshelptopreserveandexpose\ncertainconservedepitopeson HAmolecules, whicharelikelyresponsibleforthehighlevelsofbroadlycross-reactiveandprotective\nantibodieswithrarespecificitiesobservedwith RIV4. Furthermore, thepresenceofuniformcompact HAoligomersandabsenceof\neggproteins, viral RNAorprocessimpurities, typicallyfoundinconventionalvaccines, areexpectedtoeliminatepotentialadverse\nreactionstothesecomponentsinsusceptibleindividualswiththeuseof RIV4. Thesedistinctstructuralfeaturesandpurityofthe\nrecombinant HAvaccinethusprovideanumberofbenefitsinvaccineperformancewhichcanbeextendedtootherviraltargets,\nsuchasfor COVID-19."
      },
      {
        "type": "text",
        "bbox": [
          46.30133056640625,
          178.87327514648436,
          526.4232714843749,
          339.35302001953124
        ],
        "confidence": 0.9032245874404907,
        "original_box": {
          "type": "Text",
          "bbox": [
            46.30133056640625,
            178.87327514648436,
            526.4232714843749,
            339.35302001953124
          ],
          "confidence": 0.9032245874404907
        },
        "center_x": 286.3623010253906,
        "center_y": 259.1131475830078,
        "reading_order": 10,
        "content": "Theinfluenzavaccinefieldhasbeenconstantlyevolvingtoimprovethespeed,scalability,andflexibilityofmanufacturing,and\nimprovethebreadthandlongevityoftheprotectiveimmuneresponseacrossagegroups,givingrisetoanarrayofnextgenerati\nvaccinesindevelopment.Amongthese,therecombinantinfluenzavaccinetetravalent(RIV4),usingabaculovirusexpressionvec\nsystemtoexpressrecombinanthaemagglutinin(r HA)ininsectcells, istheonlyonetohavereachedthemarketandhasbeen\nstudiedextensively. Wedescribehowtheuniquestructuralfeaturesofr HAin RIV4improveprotectiveimmuneresponsescompa\ntoconventionalinfluenzavaccinesmadefrompropagatedinfluenzavirus.Inadditiontothesequenceintegrity,characteristic\nrecombinantproteins, uniquepost-translationalprocessingofther HAininsectcellsinstillsfavourabletertiaryandquaternary\nstructuralfeatures. Theabsenceofprotease-drivencleavageandadditionofsimple N-linkedglycanshelptopreserveandexp\ncertainconservedepitopeson HAmolecules, whicharelikelyresponsibleforthehighlevelsofbroadlycross-reactiveandprotect\nantibodieswithrarespecificitiesobservedwith RIV4. Furthermore, thepresenceofuniformcompact HAoligomersandabsence\neggproteins, viral RNAorprocessimpurities, typicallyfoundinconventionalvaccines, areexpectedtoeliminatepotentialadve\nreactionstothesecomponentsinsusceptibleindividualswiththeuseof RIV4. Thesedistinctstructuralfeaturesandpurityoft\nrecombinant HAvaccinethusprovideanumberofbenefitsinvaccineperformancewhichcanbeextendedtootherviraltarg\nsuchasfor COVID-19."
      },
      {
        "type": "text",
        "bbox": [
          47.62025573730469,
          181.50901611328123,
          540.682998046875,
          241.47358154296873
        ],
        "confidence": 0.8422566056251526,
        "original_box": {
          "type": "Text",
          "bbox": [
            47.62025573730469,
            181.50901611328123,
            540.682998046875,
            241.47358154296873
          ],
          "confidence": 0.8422566056251526
        },
        "center_x": 294.15162689208984,
        "center_y": 211.49129882812497,
        "reading_order": 11,
        "content": "Theinfluenzavaccinefieldhasbeenconstantlyevolvingtoimprovethespeed,scalability,andflexibilityofmanufacturing,andto\nimprovethebreadthandlongevityoftheprotectiveimmuneresponseacrossagegroups,givingrisetoanarrayofnextgeneration\nvaccinesindevelopment.Amongthese,therecombinantinfluenzavaccinetetravalent(RIV4),usingabaculovirusexpressionvector\nsystemtoexpressrecombinanthaemagglutinin(r HA)ininsectcells, istheonlyonetohavereachedthemarketandhasbeen\nstudiedextensively. Wedescribehowtheuniquestructuralfeaturesofr HAin RIV4improveprotectiveimmuneresponsescompared"
      },
      {
        "type": "title",
        "bbox": [
          23.642270507812498,
          98.54785766601562,
          536.6185400390625,
          143.76539794921874
        ],
        "confidence": 0.9803076386451721,
        "original_box": {
          "type": "Title",
          "bbox": [
            23.642270507812498,
            98.54785766601562,
            536.6185400390625,
            143.76539794921874
          ],
          "confidence": 0.9803076386451721
        },
        "center_x": 280.13040527343753,
        "center_y": 121.15662780761718,
        "reading_order": 12,
        "content": "Unique features of a recombinant haemagglutinin in uenza\nfl\nvaccine that in uence vaccine performance"
      },
      {
        "type": "text",
        "bbox": [
          301.73644775390625,
          647.5705224609375,
          549.0770800781249,
          699.584853515625
        ],
        "confidence": 0.9940469264984131,
        "original_box": {
          "type": "Text",
          "bbox": [
            301.73644775390625,
            647.5705224609375,
            549.0770800781249,
            699.584853515625
          ],
          "confidence": 0.9940469264984131
        },
        "center_x": 425.4067639160156,
        "center_y": 673.5776879882812,
        "reading_order": 13,
        "content": "The annual production of influenza vaccine through conven-\ntional, mostly egg-based platforms, is arduous and a race-\nagainst-time21. The production process, from the selection of\ninfluenza strains to vaccine manufacture and release for\ndistribution,takeseighttoninemonthseachyear.Agile,reliable"
      },
      {
        "type": "text",
        "bbox": [
          302.024091796875,
          535.9396728515625,
          551.2891113281249,
          649.046162109375
        ],
        "confidence": 0.9889411330223083,
        "original_box": {
          "type": "Text",
          "bbox": [
            302.024091796875,
            535.9396728515625,
            551.2891113281249,
            649.046162109375
          ],
          "confidence": 0.9889411330223083
        },
        "center_x": 426.6566015625,
        "center_y": 592.4929174804688,
        "reading_order": 14,
        "content": "Influenza vaccines can afford significant protection against\ninfluenza illness, even when there is an antigenic mismatch\nagainst the predominant circulating virus strains16,17. Such cross-\nprotectioncanoccurthroughtheprimingoftheimmunesystem\nby vaccination or natural infection and is primarily due to\nantibodies specific to conserved regions on the HA head and\nstem18. Vaccines that can induce immunity specific to circulating\nwild-typestrainsandcross-protectiontorelatedstrainswouldbe\nideal against constantly evolving influenza viruses. As such, the\nconserved regions on the HA head and stem present attractive\ntargetsfor developmentof universalinfluenzavaccines19,20."
      },
      {
        "type": "text",
        "bbox": [
          301.03916748046873,
          436.947626953125,
          550.0652343749999,
          542.3653564453125
        ],
        "confidence": 0.9664266109466553,
        "original_box": {
          "type": "Text",
          "bbox": [
            301.03916748046873,
            436.947626953125,
            550.0652343749999,
            542.3653564453125
          ],
          "confidence": 0.9664266109466553
        },
        "center_x": 425.55220092773436,
        "center_y": 489.65649169921875,
        "reading_order": 15,
        "content": "Thepreparationoftheannual influenzavaccinefirstly requires\nthe identification of the influenza strains and their like strains,\nmostlikelytospreadduringtheupcomingseason,forinclusionin\nthe vaccine. Identification of the target influenza strains is based\non surveillance data collected by World Health Organization\n(WHO) collaborating centres at six locations in the UK, USA\n(includingthe Centersfor Disease Controland Prevention[CDC]),\nJapan, China and Australia as part of the WHO Global Influenza\nSurveillanceand Response System(GISRS)15. Thefinaldecisionon\nresultingvaccinetargetsismadebyindividualregulatorybodies."
      },
      {
        "type": "text",
        "bbox": [
          303.16693359375,
          387.15169921874997,
          550.47779296875,
          436.31789062499996
        ],
        "confidence": 0.9860973358154297,
        "original_box": {
          "type": "Text",
          "bbox": [
            303.16693359375,
            387.15169921874997,
            550.47779296875,
            436.31789062499996
          ],
          "confidence": 0.9860973358154297
        },
        "center_x": 426.82236328125,
        "center_y": 411.73479492187494,
        "reading_order": 16,
        "content": "budding virus from the infected cells, thus serving as another\nimportant vaccine target. Although the presence of NA is not\nrequired for effective vaccine performance12, its inclusion in\nannualinfluenzavaccinationmayhelptobroadenprotectionand\nreduceinfluenzaseverity13,14."
      }
    ]
  },
  {
    "page_num": 2,
    "page_width": 595.276,
    "page_height": 790.866,
    "ordered_elements": [
      {
        "type": "text",
        "bbox": [
          45.509842529296876,
          694.815380859375,
          293.0445703125,
          735.7447705078125
        ],
        "confidence": 0.985846221446991,
        "original_box": {
          "type": "Text",
          "bbox": [
            45.509842529296876,
            694.815380859375,
            293.0445703125,
            735.7447705078125
          ],
          "confidence": 0.985846221446991
        },
        "center_x": 169.27720642089844,
        "center_y": 715.2800756835937,
        "reading_order": 1,
        "content": "Lower vaccine effectiveness estimates have been observed for\nH3N2thanforotherstrainssince2009,evenduringseasonswhen\nthe selected vaccine strain appeared to be well matched to\ncirculating strains27. Differences in HA glycosylation between the"
      },
      {
        "type": "text",
        "bbox": [
          46.45809448242187,
          472.4979345703125,
          292.37675537109374,
          695.71265625
        ],
        "confidence": 0.9943491816520691,
        "original_box": {
          "type": "Text",
          "bbox": [
            46.45809448242187,
            472.4979345703125,
            292.37675537109374,
            695.71265625
          ],
          "confidence": 0.9943491816520691
        },
        "center_x": 169.4174249267578,
        "center_y": 584.1052954101563,
        "reading_order": 2,
        "content": "Aknownriskoftraditionalsplitorsubunitvaccinesisthepotential\nfor thecandidate vaccine virus or working virus seeds to acquire\nadaptivemutationsastheygrowinembryonatedchickeneggor\nmammalianhostcellsduringvaccinemanufacture.Suchadaptive\nmutations in HA peptides may reduce the effectiveness of the\nresultant vaccine24\u201326. Raymond et al.24 showed that an egg-\nadapted A/California/07/2009 (H1N1) vaccine strain acquired a\nmutation resulting in the substitution of glutamine with arginine\nat position 226 which in turn induced antibodies specific to\nreceptorbindingsitethatboundtovaccine-derived HApreferen-\ntiallyoverthecirculatingwild-typevirus24.Duringthe2012\u20132013\nnorthernhemisphereinfluenzavaccinationcampaign,HAfroman\negg-adapted A/Victoria/361/2011 (H3N2) virus used for vaccine\nmanufacturing differed from the WHO-recommended prototype\nand several other wild-type influenza viruses in three positions,\nH156Q, G186V, and S219Y25. Thelowvaccineeffectiveness(41%)\nobserved for H3N2 in the 2012\u20132013 season was attributed to\nthese three mutations during vaccine production25. Other\nantigenicmutationsintroducedbyegg-adaptationofthevaccine\nstrain during vaccine manufacturing are thought to have\ncontributed to low vaccine effectiveness estimates for H3N2 in\notherinfluenzaseasons26,27."
      },
      {
        "type": "title",
        "bbox": [
          45.65138763427734,
          443.99970703125,
          286.7105346679687,
          474.6218115234375
        ],
        "confidence": 0.9562699198722839,
        "original_box": {
          "type": "Title",
          "bbox": [
            45.65138763427734,
            443.99970703125,
            286.7105346679687,
            474.6218115234375
          ],
          "confidence": 0.9562699198722839
        },
        "center_x": 166.18096115112303,
        "center_y": 459.3107592773438,
        "reading_order": 3,
        "content": "POTENTIALANTIGENIC MISMATCH OFINFLUENZA VACCINE\nVIRUSGROWNINEGGORCELLS DUETO ADAPTIVE\nMUTATIONSINTHEHA PRIMARY STRUCTURE"
      },
      {
        "type": "text",
        "bbox": [
          43.590830383300776,
          355.07713623046874,
          295.18969482421875,
          427.521181640625
        ],
        "confidence": 0.9945554733276367,
        "original_box": {
          "type": "Text",
          "bbox": [
            43.590830383300776,
            355.07713623046874,
            295.18969482421875,
            427.521181640625
          ],
          "confidence": 0.9945554733276367
        },
        "center_x": 169.39026260375977,
        "center_y": 391.29915893554687,
        "reading_order": 4,
        "content": "This review focuses on the structural features of BEVS-derived\nr HAthatmake RIV4uniquefromconventionalvaccines, andhow\nthese features help to maximise vaccine performance. Notably,\nthe benefits of this manufacturing process can be extended to\nother viral targets, such as COVID-19, where the preservation of\nconserved epitopes is critical for imparting cross-protection\nagainsta constantlyevolvingand mutating virus."
      },
      {
        "type": "text",
        "bbox": [
          43.48760559082031,
          56.75430541992187,
          292.7242529296875,
          357.5863256835937
        ],
        "confidence": 0.975526750087738,
        "original_box": {
          "type": "Text",
          "bbox": [
            43.48760559082031,
            56.75430541992187,
            292.7242529296875,
            357.5863256835937
          ],
          "confidence": 0.975526750087738
        },
        "center_x": 168.1059292602539,
        "center_y": 207.1703155517578,
        "reading_order": 5,
        "content": "and egg-free technologies allowing for guaranteed and faster\nmanufacture of influenza vaccines are needed to ensure timely\ndelivery for upcoming epidemic seasons and during potential\navian flu pandemics, when egg supply may be impacted. The\nadoption of alternative vaccine development approaches\n(including m RNA, vector, and recombinant protein strategies)\nin the urgent response to the COVID-19 pandemic has\ndemonstrated the feasibility of using more efficient methods to\nproducenew,effectivevaccineswithinaccelerateddevelopment\ntimelines.Therecombinantquadrivalentinfluenzavaccine(RIV4,\nFlublok\u00ae, Supemtek\u00ae [EU, Canada], Sanofi Pasteur) was the first\nlicensed influenza vaccine to be produced using recombinant\nviralproteinsinsteadofantigensderivedfromliveinfluenzavirus\n(as for inactivated split-virion and subunit vaccines). RIV4 is an\nunadjuvantedvaccinecontaining 45\u00b5gof HA/dosefromeachof\nthe four strains. The production of RIV4 is based on a novel\nproductionplatforminwhichrecombinant HA(r HA)isexpressed\nin insect cells using a baculovirus expression vector system\n(BEVS)22. In brief, expres SF+insect cells are infected with\nrecombinant baculovirus carrying the relevant influenza HA\ngenes, which are expressed under the control of a baculovirus\npolyhedrin promotor. r HA molecules from the infected cells are\nextracted using detergent and purified from the clarified cell\nextract using column chromatographies followed by Q mem-\nbrane filtration. Purified r HA is suspended in relevant buffer\nusing tangential flow filtration and passed through sterile\nfiltration for storage and formulation22. RIV4 has undergone\nextensiveclinicalassessment 23, andwasfirstapprovedby FDAin\n2013. It is now licensed in the USA, Canada, Europe, Australia,\nand various other countries."
      },
      {
        "type": "title",
        "bbox": [
          310.1854614257812,
          403.7360009765625,
          481.83956542968747,
          414.5933056640625
        ],
        "confidence": 0.9977594614028931,
        "original_box": {
          "type": "Title",
          "bbox": [
            310.1854614257812,
            403.7360009765625,
            481.83956542968747,
            414.5933056640625
          ],
          "confidence": 0.9977594614028931
        },
        "center_x": 396.01251342773435,
        "center_y": 409.1646533203125,
        "reading_order": 6,
        "content": "RECOMBINANTHA EXPRESSIONSYSTEMS"
      },
      {
        "type": "text",
        "bbox": [
          311.72923828125,
          685.0436132812499,
          559.7225244140625,
          736.803984375
        ],
        "confidence": 0.992691695690155,
        "original_box": {
          "type": "Text",
          "bbox": [
            311.72923828125,
            685.0436132812499,
            559.7225244140625,
            736.803984375
          ],
          "confidence": 0.992691695690155
        },
        "center_x": 435.72588134765624,
        "center_y": 710.923798828125,
        "reading_order": 7,
        "content": "Vaccinescontainingplant-derivedr HAeitherinsolubleformor\nin virus-like particles (VLPs) have been shown to be safe and\nimmunogenic in humans34\u201337. A plant-derived recombinant\nquadrivalent VLP (QVLP) at 30\u00b5g dose per strain was found to\nbe non-inferior in terms of vaccine efficacy against respiratory"
      },
      {
        "type": "text",
        "bbox": [
          311.50799560546875,
          413.94282714843746,
          559.34419921875,
          687.2477783203125
        ],
        "confidence": 0.9731311202049255,
        "original_box": {
          "type": "Text",
          "bbox": [
            311.50799560546875,
            413.94282714843746,
            559.34419921875,
            687.2477783203125
          ],
          "confidence": 0.9731311202049255
        },
        "center_x": 435.42609741210936,
        "center_y": 550.595302734375,
        "reading_order": 8,
        "content": "Both prokaryotic and eukaryotic expression systems have been\nused for the manufacture of r HA vaccine antigens. The first\ncandidate recombinant influenza vaccines to be successfully\nmanufactured using an Escherichia coli fermentation system\ninvolved expression of the globular head domain of the HA\nprotein genetically fused with the Toll-like receptor 5 agonist,\nSalmonella typhimurium flagellin type 229. The resultant vaccines\nelicited strong and protective antibody responses in mouse\nmodels 29. In Phase 1clinicalevaluation, aprototypicquadrivalent\nvaccine developed using this E. coli platform elicited immune\nresponses in healthy adults with favourable tolerability30. The\nE. coli expression system has been shown to generate a high\nyields of r HA (200mg/L of purified HA protein) using a minimal\nnumberofbioreactors31.Theauthorsprojectedthatthestrategy\ncould yield up to half a billion doses of vaccine per month in a\nmedium-scalepharmaceuticalproductionfacility31.Thisapproach\nwill likely shorten the entire vaccine manufacturing process32.\nHowever, E. coli-expressed r HA proteins can be subject to mis-\nfolding, contain impurities (e.g., host-cell proteins), and do not\nundergo glycosylation33. They therefore need extensive proces-\nsing to attain desired purity and to fold to their native\nconformation31. The resulting processed proteins are less\nimmunogenic than egg-derived antigens, with around a 10-fold\ngreater quantity needed to generate protective immunity in\nanimal models31. These inherent complications have prevented\nlarge scale manufacturing and eventual commercialisation of\nE. coli-expressed influenza vaccines."
      },
      {
        "type": "text",
        "bbox": [
          309.24052734375,
          263.9535864257812,
          559.002216796875,
          386.53048828125
        ],
        "confidence": 0.9972448348999023,
        "original_box": {
          "type": "Text",
          "bbox": [
            309.24052734375,
            263.9535864257812,
            559.002216796875,
            386.53048828125
          ],
          "confidence": 0.9972448348999023
        },
        "center_x": 434.12137207031253,
        "center_y": 325.24203735351557,
        "reading_order": 9,
        "content": "Recombinant DNA technology avoids the risk of the virus\nacquiring egg-or cell-adaptedmutations duringthemanufactur-\ning process as it does not use \u2018live\u2019 influenza virus. Instead, DNA\ncoding for HA is cloned from a reference virus published in the\nGlobal Initiative on Sharing All Influenza Data (GISAID) database\nandis confirmed for fidelityat theworking virus bank level28.As\nsuch, theprimaryamino-acidsequenceofther HAproducedusing\nbaculovirusorotherrecombinantexpressionsystemisidenticalto\nthe HA from the wild-type virus isolate selected for seasonal\ninfluenzavaccineproduction.Thus,theriskofantigenicmismatch\nof RIV4, orotherr HAvaccinesindevelopment, withthewildtype\ninfluenzastrain selected forvaccines is eliminated."
      },
      {
        "type": "text",
        "bbox": [
          310.0489233398437,
          55.667801513671876,
          559.6372265625,
          266.99150390625
        ],
        "confidence": 0.9887930750846863,
        "original_box": {
          "type": "Text",
          "bbox": [
            310.0489233398437,
            55.667801513671876,
            559.6372265625,
            266.99150390625
          ],
          "confidence": 0.9887930750846863
        },
        "center_x": 434.84307495117184,
        "center_y": 161.32965270996092,
        "reading_order": 10,
        "content": "vaccine strains and circulating strains are thought to have\ncontributed to this reduced vaccine effectiveness26. During the\n2014\u20132015influenzaseason, aclade 3C.2a H3N2strainpossessing\na new predicted HA glycosylation site emerged26. For the\n2016\u20132017 season,theinfluenzavaccinewasupdated toinclude\na clade 3C.2a H3N2 strain (A/Colorado/15/2014) containing\nthenewglycosylationsite26.However,thisparticularglycosylation\nsite was absent in the egg-adapted virus. Consequently, anti-\nbodies induced in humans, and in ferrets, poorly neutralised the\nglycosylated clade 3C.2a H3N2 strain26. Contrary to the egg-\nderived vaccines and as expected, r HA containing the new\nglycosylation site induced optimal levels of antibodies that\nefficiently recognised the glycosylated clade 3C.2a H3N2 virus26.\nThe chances of introducing deleterious mutations through the\nadaptation ofseedvirus duringvaccine manufacturing todayare\nlowduetothestringentqualitycontroloftheworkingseedvirus.\nIndeed,aspercurrentregulatoryrequirements,seedvirusesmust\nbe confirmed for both genetic and antigenic match with their\noriginating wild-type virus before they can be used for vaccine\nproduction.Nonetheless,thetimeittakestogenerateappropriate\nseeds could hinderthetimelyavailability ofthevaccines."
      }
    ]
  },
  {
    "page_num": 3,
    "page_width": 595.276,
    "page_height": 790.866,
    "ordered_elements": [
      {
        "type": "text",
        "bbox": [
          35.78086944580078,
          611.6582373046875,
          283.5293994140625,
          736.9537939453124
        ],
        "confidence": 0.9972500205039978,
        "original_box": {
          "type": "Text",
          "bbox": [
            35.78086944580078,
            611.6582373046875,
            283.5293994140625,
            736.9537939453124
          ],
          "confidence": 0.9972500205039978
        },
        "center_x": 159.65513442993162,
        "center_y": 674.306015625,
        "reading_order": 1,
        "content": "RIV4 is one of only two available influenza vaccines that are\negg-free. Like other recombinant vaccines, expression of HA in\ninsect cells does not depend on the generation of reassortant\ncandidate vaccine viruses selected for robust growth in embryo-\nnated eggs or mammalian cell-lines. Instead, HA genetic\nsequences from the wild-type strains selected for inclusion in\nthevaccineareinsertedintothe BEVS, fromwhichhighyieldsof\nr HA are harvested and purified (Fig. 1). This process requires less\nthan half the time (2\u20133 months) required for the manufacture of\nconventionalinfluenzavaccines42,43.Thisisacriticaladvantagefor\nthetimelysupplyofinfluenzavaccineforbothseasonalepidemics\nandinpandemicsituations.VLPshavebeenproducedsuccessfully"
      },
      {
        "type": "text",
        "bbox": [
          34.95655975341797,
          480.66433593749997,
          281.91181640625,
          614.27126953125
        ],
        "confidence": 0.9955484867095947,
        "original_box": {
          "type": "Text",
          "bbox": [
            34.95655975341797,
            480.66433593749997,
            281.91181640625,
            614.27126953125
          ],
          "confidence": 0.9955484867095947
        },
        "center_x": 158.434188079834,
        "center_y": 547.467802734375,
        "reading_order": 2,
        "content": "Several groups have explored the use of adenovirus (Ad V)\nprimarily as a replication-defective vector, for gene delivery and\ntransgeneexpressionofr HAinthehostcells. Ad Vvectorsinduce\nbothcell-mediatedandhumoralimmunityagainsttheexpresse\nprotein, providing robust protection against the targete\ndisease39\u201341.However,pre-existingoracquiredimmunityagainst\nadenovirus can hamper vaccine effectiveness by neutralising\nthe vaccine vector and clearing the vector-infected cells. Whil\nthe use of non-human adenovirus vectors could potentially\novercome this issue, Ad V vector immunity developed through\nrepeated immunisation (for example during repeated annua\ninfluenza vaccinations) can dampen the immune respons\nagainst the vaccine antigens39,40."
      },
      {
        "type": "text",
        "bbox": [
          37.768785095214845,
          300.138662109375,
          283.33423828125,
          487.17531738281247
        ],
        "confidence": 0.9855679273605347,
        "original_box": {
          "type": "Text",
          "bbox": [
            37.768785095214845,
            300.138662109375,
            283.33423828125,
            487.17531738281247
          ],
          "confidence": 0.9855679273605347
        },
        "center_x": 160.55151168823244,
        "center_y": 393.6569897460937,
        "reading_order": 3,
        "content": "illness and influenza-like illness to a quadrivalent inactivated\ninfluenza vaccine (QIV; Fluarix Quadrivalent, Glaxo Smith Kline)\ngiven at 15\u00b5g dose/strain in adults aged 18 to 64 years37.\nHowever,inconsistencyintheexpressionlevelsoftargetproteins,\ndue to nonspecific integration of transgene(s) into the host\ngenome,hasbeenamajorchallengewithplant-basedexpression\nsystems34.Theunpredictable yieldcould adversely impacttimely\nvaccineproduction,whichtypicallyinvolvesupdatingatleastone\nHA component of the vaccine to reflect antigenic change in\nthe circulating influenza viruses each season. A unique positive\nattribute of plant-derived r HA is that it can stimulate innate\nimmunity that predominantly facilitates Type 1 pro-inflammatory\ncellular immune responses, potentially as a direct effect of the\nplant-origin lipids/glycolipids in the vaccine formulation38. These\nstimulatory components in a plant-derived vaccine may need to\nbecontrolledandkeptataconstantlevel,forcommercialisation,\nto avoid potential severe adverse events caused by enhanced\nimmuneresponses invaccinees."
      },
      {
        "type": "text",
        "bbox": [
          35.03931976318359,
          263.578974609375,
          549.0259277343749,
          291.070546875
        ],
        "confidence": 0.8668315410614014,
        "original_box": {
          "type": "Text",
          "bbox": [
            35.03931976318359,
            263.578974609375,
            549.0259277343749,
            291.070546875
          ],
          "confidence": 0.8668315410614014
        },
        "center_x": 292.03262374877926,
        "center_y": 277.3247607421875,
        "reading_order": 4,
        "content": "Fig.1 Generationofr HAusingthebaculovirus-insectcellexpressionsystemforthemanufactureof RIV4. BVbaculovirus. Figureadapted\nfrom Cox, M. M.&Hashimoto, Y(2011). Afasttrackinfluenzavirusvaccineproducedininsectcells. JInvertebr Pathol 107Suppl, S31-41\u00a92011\nElsevier Inc, withpermissionfrom Elsevier 23."
      },
      {
        "type": "figure",
        "bbox": [
          87.02554504394531,
          53.83488098144531,
          527.1608935546875,
          250.0171435546875
        ],
        "confidence": 0.9968974590301514,
        "original_box": {
          "type": "Figure",
          "bbox": [
            87.02554504394531,
            53.83488098144531,
            527.1608935546875,
            250.0171435546875
          ],
          "confidence": 0.9968974590301514
        },
        "center_x": 307.0932192993164,
        "center_y": 151.92601226806642,
        "reading_order": 5
      },
      {
        "type": "text",
        "bbox": [
          300.95343017578125,
          643.51037109375,
          550.1648583984374,
          735.80203125
        ],
        "confidence": 0.9959327578544617,
        "original_box": {
          "type": "Text",
          "bbox": [
            300.95343017578125,
            643.51037109375,
            550.1648583984374,
            735.80203125
          ],
          "confidence": 0.9959327578544617
        },
        "center_x": 425.55914428710935,
        "center_y": 689.656201171875,
        "reading_order": 6,
        "content": "Influenza HA is synthesised as a single precursor polypeptide\n(HA0),whichisgenerallycleavedintotwopolypeptides(HA1and\nHA2) extracellularly by trypsin-like serine proteases, furin and\nother subtilisin family endoproteases after newly synthesised\nvirions are released from infected cells50,51. HA cleavage is\nessential for the infectivity of influenza virus. Thus, expression of\nthese proteases exclusively in the respiratory tract is responsible\nfor influenza virus tropism to epithelial cells of the upper and\nlower respiratory tract. However, HA from influenza subtypes H5"
      },
      {
        "type": "title",
        "bbox": [
          301.2702978515625,
          621.8478369140624,
          553.5061523437499,
          642.6418798828125
        ],
        "confidence": 0.9597947597503662,
        "original_box": {
          "type": "Title",
          "bbox": [
            301.2702978515625,
            621.8478369140624,
            553.5061523437499,
            642.6418798828125
          ],
          "confidence": 0.9597947597503662
        },
        "center_x": 427.38822509765623,
        "center_y": 632.2448583984375,
        "reading_order": 7,
        "content": "THETERTIARY STRUCTUREOFRECOMBINANT HA PRODUCED\nININSECTCELLSCANINFLUENCEVACCINEIMMUNOGENICITY"
      },
      {
        "type": "text",
        "bbox": [
          301.86973388671873,
          459.8144384765625,
          548.996220703125,
          603.8608447265625
        ],
        "confidence": 0.993380069732666,
        "original_box": {
          "type": "Text",
          "bbox": [
            301.86973388671873,
            459.8144384765625,
            548.996220703125,
            603.8608447265625
          ],
          "confidence": 0.993380069732666
        },
        "center_x": 425.4329772949219,
        "center_y": 531.8376416015625,
        "reading_order": 8,
        "content": "Insect cell-derived r HA (RIV4) has been studied extensively by\nvarious groups in both pre-clinical models and humans. The r HA\ncontainedin RIV4differs fromthatexpressedinother systemsin\nterms of specific structural features, the nature of the source\nmaterialandthemanufacturingprocess,whichhaveanimpacton\ncertain aspects of vaccine safety and efficacy (Fig. 2). Based on\nthese unique features, RIV4 received \u2018product exclusivity\u2019 protec-\ntion from FDA, a \u2018new active substance\u2019 designation from EMA\nCommittee for Medicinal Products for Human Use (CHMP)48 and\nan\u2018innovativedrug\u2019designationfrom Health Canada 49. Theuseof\nthis technology, together with the molecular characterisation of\nthe product, should facilitate continued evolution of influenza\nvaccines with improved effectivenessand theirtimely availability\ntothepublic."
      },
      {
        "type": "text",
        "bbox": [
          301.45941650390625,
          297.7007739257812,
          548.54947265625,
          463.5590625
        ],
        "confidence": 0.995470404624939,
        "original_box": {
          "type": "Text",
          "bbox": [
            301.45941650390625,
            297.7007739257812,
            548.54947265625,
            463.5590625
          ],
          "confidence": 0.995470404624939
        },
        "center_x": 425.00444458007814,
        "center_y": 380.62991821289063,
        "reading_order": 9,
        "content": "by integrating HA, capsid protein (M1) and neuraminidase (NA)\nexpressedininsectcells 44\u201346. Althoughpresentingproteinsin VLP\nstructures enhanced their immunogenicity, it compromised the\npurity of the vaccines considerably, as VLP structures also\nintegrated both baculovirus and Sf9 cell proteins. Elimination of\nthese unwanted proteins from the vaccine required extensive\ndisassemblyandreassemblyprocessingofpurified VLPs, whichis\na constraint for the commercial scale manufacturing of vaccines\nannually.Italso raises thecostand thetime ittakestobringthe\nvaccines to the market. The yield and the cost of various\nmanufacturing processes and technologies are critical elements\nto ensure adequate supply of vaccine at an affordable cost,\nespecially in a pandemic situation. This aspect of the vaccine\nmanufacturing has been discussed exhaustively in a report\npublished by the Program for Appropriate Technology in Health\n(PATH)and is notcovered here47."
      }
    ]
  },
  {
    "page_num": 4,
    "page_width": 595.276,
    "page_height": 790.866,
    "ordered_elements": [
      {
        "type": "text",
        "bbox": [
          45.67667816162109,
          644.1880078125,
          295.99305908203127,
          735.9500390625
        ],
        "confidence": 0.9976961016654968,
        "original_box": {
          "type": "Text",
          "bbox": [
            45.67667816162109,
            644.1880078125,
            295.99305908203127,
            735.9500390625
          ],
          "confidence": 0.9976961016654968
        },
        "center_x": 170.8348686218262,
        "center_y": 690.0690234374999,
        "reading_order": 1,
        "content": "The conformational differences between pre-fusion and post-\nfusion states of HA and the process of exposure of the fusion\npeptide have been well described54. Webster et al.57 demon-\nstrated, using monoclonal antibodies, that neutralising epitopes\npresentinthepre-fusion HA0moleculewerelostuponconversion\nto the post-fusion HA1\u2013HA2 heterodimer at an acidic p H57.\nSimilarly, several broadly neutralising antibodies directed against\nthe highly conserved HA stem region have been shown to block\nHAmaturationandfusion58.Someoftheseantibodiesarelikelyto"
      },
      {
        "type": "text",
        "bbox": [
          47.09525207519531,
          438.47230957031246,
          293.7716015625,
          643.8263378906249
        ],
        "confidence": 0.9924742579460144,
        "original_box": {
          "type": "Text",
          "bbox": [
            47.09525207519531,
            438.47230957031246,
            293.7716015625,
            643.8263378906249
          ],
          "confidence": 0.9924742579460144
        },
        "center_x": 170.43342681884766,
        "center_y": 541.1493237304687,
        "reading_order": 2,
        "content": "and H7 contains multi-basic cleavage sites that are cleaved by\nubiquitously expressed furin in the trans-Golgi network, making\nthesestrainshighlyvirulent 50,52,53. The HA1and HA2polypeptides\nremaincovalentlylinkedbyadisulfidebondtoformheterodimers\n(Fig. 2). These molecules, either uncleaved HA0 or cleaved\nHA1\u2013HA2 heterodimers, are expressed on the viral membrane\nsurface as trimers (HA \u2018rosettes\u2019). The conversion of HA0 to\nHA1\u2013HA2 heterodimers leads to conformational changes that\nrenderthemoleculefusion-competent,thusenablingthevirusto\ninfect a new host cell52,54. In inactivated (split and subunit)\nvaccines, the HAmoleculesderivedfromliveinfluenzavirusesare\npresentpredominantlyas HA1\u2013HA2heterodimers. Bycontrast, the\nr HAincludedin RIV4isdesignedtoyieldpredominantlyasasingle\nHA0polypeptide(Fig.2). Apreviousbiochemicalstudy(using SDS-\nPAGE under reducing conditions) clearly demonstrated the\npredominanceof HA0inrecombinant HAH7 subunitcomplexes,\nproducedusinga BEVS, withnoproteinbandsindicativeof HA1or\nHA2 molecules55. Poor processing of HA0 to HA1 and HA2\npolypeptidesin Sf 9cellshasbeenshowntobeduetoinsufficient\nlevelsof furin-likeproteases inthecells56."
      },
      {
        "type": "figure",
        "bbox": [
          65.79117004394531,
          52.3698046875,
          508.940771484375,
          357.55595947265624
        ],
        "confidence": 0.9955737590789795,
        "original_box": {
          "type": "Figure",
          "bbox": [
            65.79117004394531,
            52.3698046875,
            508.940771484375,
            357.55595947265624
          ],
          "confidence": 0.9955737590789795
        },
        "center_x": 287.3659707641601,
        "center_y": 204.96288208007812,
        "reading_order": 3
      },
      {
        "type": "text",
        "bbox": [
          44.27542694091797,
          370.143369140625,
          557.3605078125,
          439.2411328125
        ],
        "confidence": 0.9902216196060181,
        "original_box": {
          "type": "Text",
          "bbox": [
            44.27542694091797,
            370.143369140625,
            557.3605078125,
            439.2411328125
          ],
          "confidence": 0.9902216196060181
        },
        "center_x": 300.817967376709,
        "center_y": 404.6922509765625,
        "reading_order": 4,
        "content": "Fig.2 Structuralfeaturesofnative HAexpressedoninfluenzavirusandr HAproducedininsectcellsusingthebaculovirusexpressio\nvector system. a HA protein (shown as monomer) extracted from influenza virus is a heterodimer comprising HA1 (turquoise) and HA\n(orange)linkedthoughaninter-disulfide(S\u2013S)bondandcontainscomplex-typesialylated N-linkedglycans. Cleavedfusionpeptides(green\nandcomplexglycans 74eliminateandmaskuniqueepitopeson HArespectively. b Recombinant HAprotein(shownasmonomer)expressedi\ninsectcellsasasingleprecursorpolypeptide(HA0)withaminoacidsequenceidenticaltowildtype HAsequenceandcontainsunsialylate\npaucimannosidic N-linked glycans74. HA0 is coloured in turquoise and orange to show HA1 and HA2 segments combined as a single\npolypeptide. Uncleavedfusion-peptideloop(green)andsimplerglycanspreserveandexposeuniqueepitopesonr HA."
      },
      {
        "type": "text",
        "bbox": [
          311.44201171875,
          441.94508789062496,
          555.250078125,
          737.692822265625
        ],
        "confidence": 0.9860806465148926,
        "original_box": {
          "type": "Text",
          "bbox": [
            311.44201171875,
            441.94508789062496,
            555.250078125,
            737.692822265625
          ],
          "confidence": 0.9860806465148926
        },
        "center_x": 433.346044921875,
        "center_y": 589.818955078125,
        "reading_order": 5,
        "content": "bind near the uncleaved fusion peptide that protrudes at th\nsurfaceofthe HA0rosettes. Turneretal.59identifiedamonoclon\nantibodythatbindstoanepitopeon HAmoleculesthatarepartl\nand transiently exposed in the pre-fusion conformation5\nStructural analysis of the antigen-antibody complex revealed\npotential dynamic state where HA undergoes structural fluctua\ntions in its pre-fusion state59. A recent study by Khurana et al.6\nfurther demonstrated, using surface plasmon resonance technol\nogy, that the observed broader specificity of antibodies induce\nby RIV4 may be linked to the presence of unique epitopes o\nHA060. Additionally, severalgroupshaveisolated, using HA0asth\nimmunogenorfromaphagedisplaylibrary,protectiveantibodie\nspecific to epitopes in the fusion loop region present only i\nHA061,62. Theseantibodiesexhibited unprecedentedbreadthan\npotencyandneutralisedadiversepanelofrepresentativeviruse\ningroup 1andgroup 2influenza A, blockedproteasecleavageo\nHA0andlocked HAinthepre-fusionstate. Thus, theseantibodie\nmake the virus non-infectious by inhibiting the p H-induce\nconformation change and the HA-mediated membrane fusio\nthatareessentialforthevirusinfectivity.HAmoleculespresente\non influenza virions are predominantly in the pre-fusion stat\nOnce the virus binds to a cell or enters the acidic endosome o\ninfectedcells, thefusionloopiscleavedtoyield HA1and HA2, an\nthe hydrophobic fusion peptide in the N-terminus of HA2 i\nsequestered away from membranes in a pocket, limiting it\nexposure52,63.Nonetheless,itwouldbeofinteresttoexamineth\nimmunogenicityofreleased HAfusionpeptidesinthepost-fusio\nstateandtheirpotentialroleinprotection,asthesearepresenti\nconventional influenza vaccines. Together, these critical finding"
      }
    ]
  },
  {
    "page_num": 5,
    "page_width": 595.276,
    "page_height": 790.866,
    "ordered_elements": [
      {
        "type": "text",
        "bbox": [
          36.35095275878906,
          606.0482666015624,
          283.1363525390625,
          735.7775097656249
        ],
        "confidence": 0.9940621256828308,
        "original_box": {
          "type": "Text",
          "bbox": [
            36.35095275878906,
            606.0482666015624,
            283.1363525390625,
            735.7775097656249
          ],
          "confidence": 0.9940621256828308
        },
        "center_x": 159.74365264892577,
        "center_y": 670.9128881835936,
        "reading_order": 1,
        "content": "In Canada between 2000 and 2004, an unusual number of\ncasesofasyndrometermedasoculo-respiratorysyndrome(ORS)\nwere reported following immunisation with the inactivated\ninfluenza split-virus vaccine68. Detailed analysis revealed that\nORS, induced within 2 to 24h of vaccination, was suspected to\nbeduetothepresenceofmicro-aggregatesofunsplitvirionsin\ntheconventionalegg-derivedinfluenzavaccines69.Highlevelsof\naggregate content in the split vaccine are believed to have\ninduced a Type-2 polarised immune response resulting in ORS\nbased on study results from a mouse model70. Although\nextremely rare, this is unlikely to occur with RIV4 that contains\nHA rosettes of small and uniform size."
      },
      {
        "type": "text",
        "bbox": [
          35.208075256347655,
          502.059814453125,
          283.1239819335937,
          607.4204589843749
        ],
        "confidence": 0.9945138692855835,
        "original_box": {
          "type": "Text",
          "bbox": [
            35.208075256347655,
            502.059814453125,
            283.1239819335937,
            607.4204589843749
          ],
          "confidence": 0.9945138692855835
        },
        "center_x": 159.16602859497067,
        "center_y": 554.7401367187499,
        "reading_order": 2,
        "content": "Further characterisation by cryo-electron microscopy has\nrevealed that the HA rosette clusters in RIV4 are uniformly\nstarfish-shaped;whereasinthesplitvaccinetheyaremostlynon-\nsymmetrical and agglomerated into huge structures, resulting in\nboth starfish- and peanut-shaped heterogeneous particles55.\nAdditional electron microscopy analysis of split vaccine clusters\nshowed a highly heterogeneous mixture containing different\ntypesofviralparticlescontaining HAand NAaswellassplitviral\nmembranefoldedinvariousshapes,slightlydisruptedvirions,and\nwholevirions66."
      },
      {
        "type": "text",
        "bbox": [
          37.065292053222656,
          366.37185058593747,
          282.0563525390625,
          503.10228515625
        ],
        "confidence": 0.9897176027297974,
        "original_box": {
          "type": "Text",
          "bbox": [
            37.065292053222656,
            366.37185058593747,
            282.0563525390625,
            503.10228515625
          ],
          "confidence": 0.9897176027297974
        },
        "center_x": 159.5608222961426,
        "center_y": 434.7370678710937,
        "reading_order": 3,
        "content": "As described above, HA is expressed on the viral surface as a HA\ntrimer (rosette). When these are extracted from influenza viruses,\nthey form clusters of varying sizes. This has been observed in\nconventionalinfluenzavirus-derivedvaccines,withestimatesof18\nto 1100 trimers per cluster55,66,67. Two distinct populations of\nclusterhavebeenobserved;themajorityhaveanaveragediameter\nof 150nm, while the remainder are larger (average diameter,\n5500nm)66. However, therosetteclustersin RIV4areuniforminsize\nand presentation, containing around six to eight HA trimers per\nclusteratanaveragediameterofapproximately30\u201340nm55,67.The\nelution of r HA from RIV4 drug substance as a single peak in size-\nexclusion high-performance liquid chromatography is monitored\nforthereleaseandthestabilityof RIV4."
      },
      {
        "type": "title",
        "bbox": [
          35.81140869140625,
          335.4143115234375,
          283.49830810546877,
          365.23946777343747
        ],
        "confidence": 0.9188194274902344,
        "original_box": {
          "type": "Title",
          "bbox": [
            35.81140869140625,
            335.4143115234375,
            283.49830810546877,
            365.23946777343747
          ],
          "confidence": 0.9188194274902344
        },
        "center_x": 159.6548583984375,
        "center_y": 350.3268896484375,
        "reading_order": 4,
        "content": "THEHOMOGENEITYOFRECOMBINANTHAANTIGENSINRIV4\nMAYIMPROVE THESAFETYPROFILE OVERCONVENTIONAL\nINFLUENZAVACCINES"
      },
      {
        "type": "text",
        "bbox": [
          36.17580322265625,
          97.22513671875,
          286.5204711914062,
          298.7607788085937
        ],
        "confidence": 0.9864022135734558,
        "original_box": {
          "type": "Text",
          "bbox": [
            36.17580322265625,
            97.22513671875,
            286.5204711914062,
            298.7607788085937
          ],
          "confidence": 0.9864022135734558
        },
        "center_x": 161.34813720703124,
        "center_y": 197.99295776367185,
        "reading_order": 5,
        "content": "Structural differences in the HA polypeptides and rosettes\nbetween recombinant and split vaccines have been shown to\nresult in differences, both qualitative and quantitative, in the\nimmune response to vaccines in humans and animals. Portnoff\net al.64 demonstrated that recombinant HA antigens (specifically\nforthe H3strain)producedusing BEVS(asusedfor RIV4), induced\nsignificantly higher levels of broadly cross-reactive antibodies\nagainst highly conserved regions of the HA head and stem\ndomains than egg-derived split vaccines64. Recently Richards\net al.65 examined CD4 T-cell and antibody responses in healthy\nadults who received egg-derived split vaccine, cell-derived split\nvaccineor RIV4forthreesuccessiveinfluenzaseasons(2015\u20132016,\n2016\u20132017, and 2017\u20132018)65. RIV4 elicited the most robust\nresponses, withsignificantlyhigher T-cellandantibodylevelsthan\ntheothertwovaccines.Authorspostulatedthatsimplerglycosyla-\ntion of r HA and absence of other influenza viral proteins in RIV4\ncontributedtotheobservedrobustimmuneresponsefor RIV4and\nemphasised the relevance of these features in determining\nvaccineefficacyand long-term immunity65."
      },
      {
        "type": "text",
        "bbox": [
          35.66513122558594,
          58.02353942871093,
          286.1814111328125,
          98.60310791015624
        ],
        "confidence": 0.9610600471496582,
        "original_box": {
          "type": "Text",
          "bbox": [
            35.66513122558594,
            58.02353942871093,
            286.1814111328125,
            98.60310791015624
          ],
          "confidence": 0.9610600471496582
        },
        "center_x": 160.92327117919922,
        "center_y": 78.31332366943359,
        "reading_order": 6,
        "content": "clearlydemonstrate structural differences between HApre-fusion\nand post-fusion states, and the presence of unique neutralising\nepitopes in the pre-fusion HA0 molecules, which are present in\nRIV4(Fig.2)."
      },
      {
        "type": "text",
        "bbox": [
          301.18840576171874,
          548.797060546875,
          550.1032470703125,
          735.3944384765625
        ],
        "confidence": 0.9924058318138123,
        "original_box": {
          "type": "Text",
          "bbox": [
            301.18840576171874,
            548.797060546875,
            550.1032470703125,
            735.3944384765625
          ],
          "confidence": 0.9924058318138123
        },
        "center_x": 425.6458264160156,
        "center_y": 642.0957495117187,
        "reading_order": 7,
        "content": "RIV4 has a unique ability to induce broadly cross-reactive\nantibody responses to antigenically drifted A/H3N2 viruses in\nhumans. In a small study by Belongia et al.82, participants aged\n65\u201374 years were immunised with RIV4, a high-dose split-virion\ninactivated trivalent influenza vaccine (Fluzone\u00ae High Dose,\nSanofi Pasteur; HD-IIV3) or adjuvanted-IIV3 (a IIV3)82. Participant\nsera were tested against four A/H3N2 viruses including a cell-\npropagated referencevaccinestrain, twocirculatingviruses and\nanantigenicallyadvanced viruswithevidenceofantigenicdrift.\nThe post-vaccination geometric mean fold rise against the two\ncirculating viruses was twice as high for RIV4 as for HD-IIV3 or\na IIV3. Post-vaccination titre against the antigenically drifted\nH3N2weregenerallylowandsimilaracrossallgroups,however,\nreceipt of RIV4 was strongly associated with seroconversion to\nthisstrain(p=0.003).Theinvestigatorssuggestedthatalthough\nthe circulating A/H3N2 viruses were antigenically similar to the\ncell-grown vaccine reference virus, egg propagation of the\nvaccine strains had led to loss of a glycosylation site and"
      },
      {
        "type": "text",
        "bbox": [
          300.73743896484376,
          399.57552246093746,
          547.407421875,
          550.716064453125
        ],
        "confidence": 0.9970153570175171,
        "original_box": {
          "type": "Text",
          "bbox": [
            300.73743896484376,
            399.57552246093746,
            547.407421875,
            550.716064453125
          ],
          "confidence": 0.9970153570175171
        },
        "center_x": 424.07243041992183,
        "center_y": 475.14579345703123,
        "reading_order": 8,
        "content": "In a study by Nachbagauer et al.78, RIV4 induced HA stem\nspecificneutralisingantibodiesdirectedagainstinfluenzasubtype\nH1, H3 and B haemagglutinin in an age-dependent manner i\nhumans,withthehighesttitresobservedintheelderly78.RIV4als\ninducesantibodies,inbothhumansandmice,thatarespecifict\nepitopes in the HA head region, at greater proportions than\ntraditional mammalian cell-derived subunit vaccine (Flucelvax\n[Trivalent])77. Higher magnitudes of haemagglutination inhibitor\nantibodyresponseagainst HA1havealsobeenobservedwith RIV\ncompared to egg- or mammalian cell-derived split vaccine\n(Flucelvax\u00ae Tetra, Seqirus, and Fluzone\u00ae quadrivalent SD, Sano\nPasteur)60.Thesedatawarrantadditionalstudiestoverifywhethe\nr HA elicits a broader antibody repertoire than conventiona\nvaccines and whether this underlies the cross-protection agains\n12,81"
      },
      {
        "type": "text",
        "bbox": [
          303.173349609375,
          236.40958740234373,
          548.0217773437499,
          401.0730029296875
        ],
        "confidence": 0.9957446455955505,
        "original_box": {
          "type": "Text",
          "bbox": [
            303.173349609375,
            236.40958740234373,
            548.0217773437499,
            401.0730029296875
          ],
          "confidence": 0.9957446455955505
        },
        "center_x": 425.59756347656247,
        "center_y": 318.7412951660156,
        "reading_order": 9,
        "content": "The peptide sequences around glycosylation sites are highly\nconservedand,assuch,antibodiesdirectedagainsttheseregions\ncould provide broader specificity. Antisera raised against simple\nmonoglycosylated HAinmicewereshowntoimprovethebreadth\nand capacity of HA-neutralising antibodies to protect against\nlethal challenge with H5N1 compared to antisera raised against\nfully glycosylated HA75. Thus, elimination of parts of glycans that\nare not essential for HA structure may improve vaccine-induced\nprotection. Subsequent studies showed that HA with simpler\nglycans induce more broadly protective antibodies with superior\ncross-clade protection compared to HA with more complex\nglycans76\u201379. The presence of simpler glycans appears to be\nequally efficient to that of chicken or mammalian cell-derived\nglycosylation in ensuring the proper folding of HA, and exposes\nconservedregionsofthemoleculefortheinductionofimmunity\nwithbroader protection12,71,76\u201380."
      },
      {
        "type": "text",
        "bbox": [
          302.72625,
          84.34361206054687,
          549.2882373046875,
          240.71675537109374
        ],
        "confidence": 0.9911256432533264,
        "original_box": {
          "type": "Text",
          "bbox": [
            302.72625,
            84.34361206054687,
            549.2882373046875,
            240.71675537109374
          ],
          "confidence": 0.9911256432533264
        },
        "center_x": 426.00724365234373,
        "center_y": 162.5301837158203,
        "reading_order": 10,
        "content": "Influenza HAhasavariablenumberof N-linkedglycosylationsites\n(dependingonthevirusstrainandsubtype)intheglobularhead\nregionandtheconservedstemregion 71. Theglycosylationof HA\nhas various functions, including regulation of the virus life-cycle\nandaroleindiseasepathogenesis71.Duringvaccinemanufacture,\nthe host cells used for the production of HA play a major role in\ndetermining HA N-glycan composition72,73. Glycoproteins\nexpressed in mammalian cells typically have sialylated complex-\ntype N-linked glycans, while those expressed in insect cells\ntypically have simple unsialylated glycans (either truncated,\npaucimannosidic or oligomannosidic glycans)74. An et al.72\nshowed that egg-derived and mammalian (Madin-Darby canine\nkidney)cell-derived HApredominantlycontainedhighly-branched\ncomplex or high-mannose glycans, whereas HA expressed in Sf9\ninsectcells had relativelysmallpaucimannose glycans (Fig. 2)72."
      },
      {
        "type": "title",
        "bbox": [
          299.89037109375,
          56.7614794921875,
          545.5100830078125,
          87.03180725097656
        ],
        "confidence": 0.9655909538269043,
        "original_box": {
          "type": "Title",
          "bbox": [
            299.89037109375,
            56.7614794921875,
            545.5100830078125,
            87.03180725097656
          ],
          "confidence": 0.9655909538269043
        },
        "center_x": 422.7002270507812,
        "center_y": 71.89664337158203,
        "reading_order": 11,
        "content": "THEN-LINKED GLYCAN STRUCTUREOFRECOMBINANT HA\nPRODUCED ININSECT CELLS DIFFERS SIGNIFICANTLY FROM\nHAINOTHERINFLUENZA VACCINES"
      }
    ]
  },
  {
    "page_num": 6,
    "page_width": 595.276,
    "page_height": 790.866,
    "ordered_elements": [
      {
        "type": "title",
        "bbox": [
          44.721430664062495,
          702.6099169921874,
          104.87681762695313,
          713.634169921875
        ],
        "confidence": 0.9971299767494202,
        "original_box": {
          "type": "Title",
          "bbox": [
            44.721430664062495,
            702.6099169921874,
            104.87681762695313,
            713.634169921875
          ],
          "confidence": 0.9971299767494202
        },
        "center_x": 74.79912414550782,
        "center_y": 708.1220434570312,
        "reading_order": 1,
        "content": "CONCLUSIONS"
      },
      {
        "type": "text",
        "bbox": [
          43.785129089355465,
          715.657060546875,
          294.8968212890625,
          735.8655322265624
        ],
        "confidence": 0.9649184346199036,
        "original_box": {
          "type": "Text",
          "bbox": [
            43.785129089355465,
            715.657060546875,
            294.8968212890625,
            735.8655322265624
          ],
          "confidence": 0.9649184346199036
        },
        "center_x": 169.34097518920896,
        "center_y": 725.7612963867186,
        "reading_order": 2,
        "content": "The evidence reviewed here demonstrates several advantages of\nthe BEVS used in the manufacture of RIV4 over conventional"
      },
      {
        "type": "text",
        "bbox": [
          45.863709411621095,
          594.3571435546875,
          294.6070239257812,
          684.7966845703124
        ],
        "confidence": 0.9977753758430481,
        "original_box": {
          "type": "Text",
          "bbox": [
            45.863709411621095,
            594.3571435546875,
            294.6070239257812,
            684.7966845703124
          ],
          "confidence": 0.9977753758430481
        },
        "center_x": 170.23536666870115,
        "center_y": 639.5769140625,
        "reading_order": 3,
        "content": "Although uncommon, some individuals may be at increased\nrisk of hypersensitivity reactions to component proteinssuchas\novalbuminandthosewhoaresensitisedmaybeathigherriskof\nclinical manifestations of allergic disease upon exposure92. Egg\nprotein, viral RNA, and process impurities such as inactivating\nagents or hydrocortisone that are typically present in conven-\ntional vaccines are absent in RIV4 would eliminate potential\nadverse reactions, although rare, to these components in\nvulnerable individuals93."
      },
      {
        "type": "text",
        "bbox": [
          45.05977111816406,
          465.62910644531246,
          293.1829541015625,
          596.8121044921875
        ],
        "confidence": 0.9941898584365845,
        "original_box": {
          "type": "Text",
          "bbox": [
            45.05977111816406,
            465.62910644531246,
            293.1829541015625,
            596.8121044921875
          ],
          "confidence": 0.9941898584365845
        },
        "center_x": 169.12136260986327,
        "center_y": 531.2206054687499,
        "reading_order": 4,
        "content": "As most split and subunit vaccines are prepared from influenza\nvirusesthataregrowninembryonatedchickeneggs,theycontain\negg proteins. Testing of 58 vaccine lots covering six different\nseasonal influenza vaccines produced by five different manufac-\nturers showed that the median ovalbumin concentration was\n350ng/m L89. Moreover, another study of commercial influenza\nvaccine preparations detected other viral proteins such as\nnucleoprotein and matrix protein (confirmed by a chromato-\ngraphicseparation)thatarenotshowntoberelevantforvaccine\neffectiveness, and viral RNA fragments (confirmed by activity\nassay)90,91. Such egg-derived or other influenza virus-derived\nproteins (as described above) and influenza viral RNA fragments\narenot present inrecombinant vaccines."
      },
      {
        "type": "title",
        "bbox": [
          45.71754180908203,
          433.43995605468746,
          293.377236328125,
          463.6290673828125
        ],
        "confidence": 0.9584028720855713,
        "original_box": {
          "type": "Title",
          "bbox": [
            45.71754180908203,
            433.43995605468746,
            293.377236328125,
            463.6290673828125
          ],
          "confidence": 0.9584028720855713
        },
        "center_x": 169.5473890686035,
        "center_y": 448.53451171874997,
        "reading_order": 5,
        "content": "ABSENCEOFEGGOROTHERINFLUENZAVIRALCOMPONENTS\nINRECOMBINANT HA VACCINE ISLIKELY TO FAVOUR ITS\nSAFETYPROFILE"
      },
      {
        "type": "text",
        "bbox": [
          45.538530578613276,
          316.020234375,
          294.84613037109375,
          415.54604003906246
        ],
        "confidence": 0.9683619737625122,
        "original_box": {
          "type": "Text",
          "bbox": [
            45.538530578613276,
            316.020234375,
            294.84613037109375,
            415.54604003906246
          ],
          "confidence": 0.9683619737625122
        },
        "center_x": 170.19233047485352,
        "center_y": 365.78313720703125,
        "reading_order": 6,
        "content": "Inallconventionalinfluenzavaccines,whetherderivedfromeggs\nor mammalian cells, the antigens are exposed to inactivation\nagents such as formaldehyde or \u03b2-propiolactone (BPL). These\ninactivatingagentscausenumerousmodificationstotheantigenic\nepitopeson HAthroughcross-linkingorformationofbis-alkylated\ngroups85\u201387.Thesemodificationsoftenresultinchangestoprotein\nfolding, conformation, and stability88. Unlike conventional vac-\ncines, RIV4 does not go through an inactivation step, thus\npreserving the native HA conformation of the wild-type virus,\nrequiredfor optimalprotective immuneresponse."
      },
      {
        "type": "title",
        "bbox": [
          46.4923828125,
          294.08561279296873,
          272.50925537109373,
          315.16677246093747
        ],
        "confidence": 0.9940453767776489,
        "original_box": {
          "type": "Title",
          "bbox": [
            46.4923828125,
            294.08561279296873,
            272.50925537109373,
            315.16677246093747
          ],
          "confidence": 0.9940453767776489
        },
        "center_x": 159.50081909179687,
        "center_y": 304.62619262695307,
        "reading_order": 7,
        "content": "RECOMBINANTHA ANTIGENSARENOT SUBJECTED TO\nCHEMICALMODIFICATIONS"
      },
      {
        "type": "text",
        "bbox": [
          45.55305725097656,
          73.37817993164062,
          294.63662109374997,
          276.20299072265624
        ],
        "confidence": 0.9614008665084839,
        "original_box": {
          "type": "Text",
          "bbox": [
            45.55305725097656,
            73.37817993164062,
            294.63662109374997,
            276.20299072265624
          ],
          "confidence": 0.9614008665084839
        },
        "center_x": 170.09483917236327,
        "center_y": 174.79058532714842,
        "reading_order": 8,
        "content": "Inadditionto the above referenced studies,ina recent study\nby Shinde et al.83 baculovirus-expressed r HA generated cross-\nprotective responses against both circulating and drifted\nA/H3N2 strains, including in older adults who are at a higher\nriskforinfluenzaandassociatedmedicalcomplications83,84.This\nuniquecharacteristicoftherecombinantvaccineislikelyrelated\ntoglycosylationofr HAintheinsectcellline, leavingituncleaved.\nThe higher quantity and greater accessibility of the genetically\nconservedstemregionofr HAproducedininsectcells(resulting\nin smaller N-linked glycans) may contribute to cross-protection\nagainstmismatchedinfluenzastrains12,75.Thestudy by Nachba-\ngaeur et al.78 supports the hypothesis that a recombinant\nvaccineresultsinincreasedtitreofbroadlyneutralising HAstem-\nreactive antibodies and that these immune responses increase\nwith age78. This increase with age is possibly due to repeated\nexposuretodivergentinfluenzavirusessimilartothemultiple A/\nH3N2 virus strains evaluated by Belongia et al.82. Therefore,\nvaccine constructs that preserve the highly conserved HA stem\ncanprotectagainstdriftedvirusesandthusmayconferagreater\nbreadth of protection against influenza."
      },
      {
        "type": "title",
        "bbox": [
          44.51585723876953,
          58.336765136718746,
          295.7469873046875,
          77.497119140625
        ],
        "confidence": 0.6234096884727478,
        "original_box": {
          "type": "Title",
          "bbox": [
            44.51585723876953,
            58.336765136718746,
            295.7469873046875,
            77.497119140625
          ],
          "confidence": 0.6234096884727478
        },
        "center_x": 170.1314222717285,
        "center_y": 67.91694213867187,
        "reading_order": 9,
        "content": "impaired antibody response to circulating viruses, consistent\nwith previous reports26."
      },
      {
        "type": "text",
        "bbox": [
          43.47267242431641,
          58.48276245117187,
          291.59402343749997,
          77.26831237792969
        ],
        "confidence": 0.7472254037857056,
        "original_box": {
          "type": "Text",
          "bbox": [
            43.47267242431641,
            58.48276245117187,
            291.59402343749997,
            77.26831237792969
          ],
          "confidence": 0.7472254037857056
        },
        "center_x": 167.53334793090818,
        "center_y": 67.87553741455078,
        "reading_order": 10,
        "content": "impaired antibody response to circulating viruses, consistent\nwith previous reports26."
      },
      {
        "type": "title",
        "bbox": [
          311.44350585937497,
          335.59995849609373,
          361.82335693359374,
          345.64928466796874
        ],
        "confidence": 0.978653073310852,
        "original_box": {
          "type": "Title",
          "bbox": [
            311.44350585937497,
            335.59995849609373,
            361.82335693359374,
            345.64928466796874
          ],
          "confidence": 0.978653073310852
        },
        "center_x": 336.63343139648435,
        "center_y": 340.62462158203124,
        "reading_order": 11,
        "content": "REFERENCES"
      },
      {
        "type": "title",
        "bbox": [
          311.7868505859375,
          254.60624267578123,
          392.5760888671875,
          265.2382177734375
        ],
        "confidence": 0.9969758987426758,
        "original_box": {
          "type": "Title",
          "bbox": [
            311.7868505859375,
            254.60624267578123,
            392.5760888671875,
            265.2382177734375
          ],
          "confidence": 0.9969758987426758
        },
        "center_x": 352.18146972656245,
        "center_y": 259.9222302246094,
        "reading_order": 12,
        "content": "DATAAVAILABILITY"
      },
      {
        "type": "text",
        "bbox": [
          312.0809545898437,
          287.3136840820312,
          517.2846240234375,
          308.33549560546874
        ],
        "confidence": 0.9295899868011475,
        "original_box": {
          "type": "Text",
          "bbox": [
            312.0809545898437,
            287.3136840820312,
            517.2846240234375,
            308.33549560546874
          ],
          "confidence": 0.9295899868011475
        },
        "center_x": 414.6827893066406,
        "center_y": 297.82458984375,
        "reading_order": 13,
        "content": "Received:24May2021; Accepted: 3November 2021;"
      },
      {
        "type": "title",
        "bbox": [
          309.91581298828123,
          266.90934814453124,
          447.21382324218746,
          276.29369384765624
        ],
        "confidence": 0.9608618021011353,
        "original_box": {
          "type": "Title",
          "bbox": [
            309.91581298828123,
            266.90934814453124,
            447.21382324218746,
            276.29369384765624
          ],
          "confidence": 0.9608618021011353
        },
        "center_x": 378.56481811523435,
        "center_y": 271.60152099609377,
        "reading_order": 14,
        "content": "Nodataweregeneratedforthereviewarticle."
      },
      {
        "type": "text",
        "bbox": [
          314.8402368164062,
          715.3577490234375,
          559.8282568359375,
          733.2585205078125
        ],
        "confidence": 0.6996215581893921,
        "original_box": {
          "type": "Text",
          "bbox": [
            314.8402368164062,
            715.3577490234375,
            559.8282568359375,
            733.2585205078125
          ],
          "confidence": 0.6996215581893921
        },
        "center_x": 437.33424682617186,
        "center_y": 724.308134765625,
        "reading_order": 15,
        "content": "7. Tricco,A.C.etal.Comparinginfluenzavaccineefficacyagainstmismatchedand\nmatchedstrains:asystematicreviewandmeta-analysis.BMCMed.11,153(2013)."
      },
      {
        "type": "list",
        "bbox": [
          306.43701416015625,
          354.14123291015625,
          561.704677734375,
          726.760810546875
        ],
        "confidence": 0.9892112016677856,
        "original_box": {
          "type": "List",
          "bbox": [
            306.43701416015625,
            354.14123291015625,
            561.704677734375,
            726.760810546875
          ],
          "confidence": 0.9892112016677856
        },
        "center_x": 434.07084594726564,
        "center_y": 540.4510217285156,
        "reading_order": 16,
        "content": "mortality:amodellingstudy.Lancet391,1285\u20131300(2018).\n2. World Health Organization. Fact-sheet. Influenza(Seasonal). Availableathttps://\nwww.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal).Accessed12\nMarch2021.(2018).\n3. Lafond,K.E.etal.Globalburdenofinfluenza-associatedlowerrespiratorytract\ninfections and hospitalizations among adults: a systematic review and meta-\nanalysis. PLo SMed.18, e 1003550(2021).\n4. US Centers for Disease Control and Prevention (CDC). Weekly U.S. Influenza\nSurveillance Report. https://www.cdc.gov/flu/weekly/index.htm. Accessed 16\nMarch2021.\n5. Sellers,S.A.,Hagan,R.S.,Hayden,F.G.&Fischer,W.A.IIThehiddenburdenof\ninfluenza:areviewoftheextra-pulmonarycomplicationsofinfluenzainfection.\nInfluenza Other Respir. Viruses 11,372\u2013393(2017).\n6. de Francisco Shapovalova, N., Donadel, M., Jit, M.&Hutubessy, R. Asystematic\nreview of the social and economic burden of influenza in low- and middle-\nincomecountries.Vaccine33,6537\u20136544(2015).\n7. Szucs,T.Thesocio-economicburdenofinfluenza.J.Antimicrob.Chemother.44\nSuppl B,11\u201315(1999).\n8. Krammer,F.etal.Influenza.Nat.Rev.Dis.Prim.4,3(2018).\n9. Paules,C.&Subbarao,K.Influenza.Lancet390,697\u2013708(2017).\n10. Hobson, D., Curry, R. L., Beare, A. S. & Ward-Gardner, A. The role of serum\nhaemagglutination-inhibitingantibodyinprotectionagainstchallengeinfection\nwithinfluenza A2and Bviruses. Epidemiol. Infect.70,767\u2013777(1972).\n11. Ohmit,S.E.etal.Influenzahemagglutination-inhibitionantibodytiterasacor-\nrelateofvaccine-inducedprotection.J.Infect.Dis.204,1879\u20131885(2011).\n12. Dunkle,L.M.etal.Efficacyofrecombinantinfluenzavaccineinadults50yearsof\nageorolder.N.Engl.J.Med.376,2427\u20132436(2017).\n13. Wohlbold,T.J.&Krammer,F.Intheshadowofhemagglutinin:agrowinginterest\nin influenza viral neuraminidase and its role as a vaccine antigen. Viruses 6,\n2465\u20132494(2014).\n14. Giurgea, L. T., Morens, D. M., Taubenberger, J. K. & Memoli, M. J. Influenza\nneuraminidase:aneglectedproteinanditspotentialforabetterinfluenzavac-\ncine.Vaccines8,409(2020).\n15. World Health Organization. Global Influenza Surveillanceand Response System\n(GISRS). Available at https://www.who.int/influenza/gisrs_laboratory/en/. Acces-\nsed17February2021.(2021).\n16. Camilloni,B.,Neri,M.,Lepri,E.&Iorio,A.M.Cross-reactiveantibodiesinmiddle-\nagedandelderlyvolunteersafter MF59-adjuvantedsubunittrivalentinfluenza\nvaccineagainst Bvirusesofthe B/Victoriaor B/Yamagatalineages. Vaccine 27,\n4099\u20134103(2009).\n17. Tricco,A.C.etal.Comparinginfluenzavaccineefficacyagainstmismatchedand"
      },
      {
        "type": "text",
        "bbox": [
          310.41509765625,
          58.06283203125,
          560.1719970703125,
          236.82287109375
        ],
        "confidence": 0.9835387468338013,
        "original_box": {
          "type": "Text",
          "bbox": [
            310.41509765625,
            58.06283203125,
            560.1719970703125,
            236.82287109375
          ],
          "confidence": 0.9835387468338013
        },
        "center_x": 435.2935473632813,
        "center_y": 147.44285156249998,
        "reading_order": 17,
        "content": "influenzavaccinesthatrelyoninfluenzavirionspropagatedinegg\normammaliancells, splitwithdetergentswithorwithoutfurther HA\nenrichment.Theuseofrecombinantproteintechnologyeliminates\ntheriskofantigenicmismatchduetopotentialchangesinprimary\nHA structure through egg- or cell-adaptation. We also describe\nfeaturesofther HAtertiarystructurethatarelikelytoberesponsible\nforthegenerationofbroadcross-reactiveandprotectiveantibodies,\ntogether with the direct or indirect evidence supporting this. The\nhomogeneity of r HA rosettes and negligible process-related\nimpurities are the hallmarks of RIV4. As r HA production bypasses\nthe need for a viral inactivation step and avoids the use of eggs,\nrelated process-impurities such as inactivating agents or residual\negg-protein, and thus potential adverse reactions to these\nimpurities in vulnerable individuals are eliminated. This well-\nestablished and validated platform for vaccine manufacture could\nbeextended to addressotheremerging infectious diseaseswhere\ncross-protectionagainstconstantlyevolvingvariantsiscritical,such\naspandemicinfluenzaand/or COVID-19."
      }
    ]
  },
  {
    "page_num": 7,
    "page_width": 595.276,
    "page_height": 790.866,
    "ordered_elements": [
      {
        "type": "list",
        "bbox": [
          34.23059143066406,
          228.61193115234374,
          283.99352783203125,
          719.768935546875
        ],
        "confidence": 0.8955439925193787,
        "original_box": {
          "type": "List",
          "bbox": [
            34.23059143066406,
            228.61193115234374,
            283.99352783203125,
            719.768935546875
          ],
          "confidence": 0.8955439925193787
        },
        "center_x": 159.11205963134765,
        "center_y": 474.1904333496094,
        "reading_order": 1,
        "content": "with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in\ncirculatingviruses. PLo SONE9, e 92153(2014).\n26. Zost, S. J. etal. Contemporary H3N2influenzaviruseshaveaglycosylationsite\nthataltersbindingofantibodieselicitedbyegg-adaptedvaccinestrains.Proc.\nNatl Acad. Sci. USA114,12578\u201312583(2017).\n27. Flannery, B. et al. Interim estimates of 2016-17 seasonal influenza vaccine\neffectiveness-United States, February 2017. MMWRMorb. Mortal. Wkly Rep.66,\n167\u2013171(2017).\n28. Shu, Y.&Mc Cauley, J. GISAID: Globalinitiativeonsharingallinfluenzadata-from\nvisiontoreality. Eurosurveillance: bulletin Europeensurlesmaladiestransmis-\nsibles = European communicable disease bulletin 22, https://doi.org/10.2807/\n1560-7917.Es.2017.22.13.30494(2017).\n29. Song,L.etal.Efficaciousrecombinantinfluenzavaccinesproducedbyhighyield\nbacterial expression: a solution to global pandemic and seasonal needs. PLo S\nONE3,e2257(2008).\n30. Tussey, L. et al. Phase 1 safety and immunogenicity study of a quadrivalent\nseasonal flu vaccine comprising recombinant hemagglutinin-flagellin fusion\nproteins. Open Forum Infect. Dis.3, ofw 015(2016).\n31. Aguilar-Yanez, J. M. et al. An influenza A/H1N1/2009 hemagglutinin vaccine\nproducedin Escherichiacoli. PLo SONE5, e 11694(2010).\n32. Saczynska, V.Influenzavirus hemagglutinin asavaccine antigen produced in\nbacteria. Acta Biochim Pol.61,561\u2013572(2014).\n33. Davis, A. R. et al. Immune response to human influenza virus hemagglutinin\nexpressedin Escherichiacoli. Gene 21,273\u2013284(1983).\n34. Rosales-Mendoza,S.etal.Whatdoesplant-basedvaccinetechnologyoffertothe\nfightagainst COVID-19? Vaccines 8,183(2020).\n35. Pillet,S.etal.Aplant-derivedquadrivalentviruslikeparticleinfluenzavaccine\ninduces cross-reactive antibody and T cell response in healthy adults. Clin.\nImmunol.168,72\u201387(2016).\n36. Pillet,S.etal.Immunogenicityandsafetyofaquadrivalentplant-derivedvirus\nlikeparticleinfluenzavaccinecandidate-tworandomized Phase IIclinicaltrialsin\n18to 49and>/=50yearsoldadults. PLo SONE14, e 0216533(2019).\n37. Ward,B.J.etal.Efficacy,immunogenicity,andsafetyofaplant-derived,quad-\nrivalent, virus-like particle influenza vaccine in adults (18-64 years) and older\nadults (>/=65 years): two multicentre, randomised phase 3 trials. Lancet 396,\n1491\u20131503(2020).\n38. Won, S. Y. et al. Characterization of the innate stimulatory capacity of plant-\nderived virus-like particles bearing influenza hemagglutinin. Vaccine 36,\n8028\u20138038(2018).\n39. Pandey,A.etal.Impactofpreexistingadenovirusvectorimmunityonimmu-\nnogenicityandprotectionconferredwithanadenovirus-based H5N1influenza\nvaccine. PLo SONE7, e 33428\u2013e 33428(2012).\n40. Sayedahmed, E. E. etal.Adenoviral vector-based vaccine platforms for devel-\nopingthenextgenerationofinfluenzavaccines.Vaccines8,574(2020).\n41. Xiang, K. et al. Progress on adenovirus-vectored universal influenza vaccines.\nHum. Vaccin Immunother.11,1209\u20131222(2015).\n42. Chen,J.R.etal.Betterinfluenzavaccines:anindustryperspective.J.Biomed.Sci.\n27,33(2020).\n43. Report to the president on reengeneering the influenza vaccine production\nenterprisetomeetthechallengesofpandemicinfluenza.Availableathttps://\nobamawhitehouse.archives.gov/sites/default/files/microsites/ostp/PCAST-\nInfluenza-Vaccinology-Report. pdf. Accessed August 2021.\n44. L\u00f3pez-Mac\u00edas,C.etal.Safetyandimmunogenicityofavirus-likeparticlepan-\ndemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-\ncontrolledtrialofadultsin Mexico. Vaccine 29,7826\u20137834(2011)."
      },
      {
        "type": "list",
        "bbox": [
          33.785266113281246,
          69.980888671875,
          283.9118994140625,
          473.15724609374996
        ],
        "confidence": 0.8753602504730225,
        "original_box": {
          "type": "List",
          "bbox": [
            33.785266113281246,
            69.980888671875,
            283.9118994140625,
            473.15724609374996
          ],
          "confidence": 0.8753602504730225
        },
        "center_x": 158.84858276367186,
        "center_y": 271.5690673828125,
        "reading_order": 2,
        "content": "de nedbyavaccine-inducedantibody. Proc. Natl Acad. Sci. USA115,168 173\n(2018).\n19. Sautto, G. A., Kirchenbaum, G. A. & Ross, T. M. Towards a universal influenza\nvaccine:differentapproachesforonegoal.Virol.J.15,17(2018).\n20. Nachbagauer,R.etal.Achimerichemagglutinin-baseduniversalinfluenzavirus\nvaccine approach induces broad and long-lasting immunity in a randomized,\nplacebo-controlledphase Itrial. Nat. Med.27,106\u2013114(2021).\n21. Orenstein,W.A.&Schaffner,W.Lessonslearned:roleofinfluenzavaccinepro-\nduction,distribution,supply,anddemand\u2013whatitmeansfortheprovider.Am.J.\nMed.121,S22\u2013S27(2008).\n22. Felberbaum, R. S. The baculovirus expression vector system: a commercial\nmanufacturingplatformforviralvaccinesandgenetherapyvectors.Biotechnol.J.\n10,702\u2013714(2015).\n23. Cox,M.M.&Hashimoto,Y.Afasttrackinfluenzavirusvaccineproducedininsect\ncells.J.Invertebr.Pathol.107,S31\u2013S41(2011).\n24. Raymond,D.D.etal.Influenzaimmunizationelicitsantibodiesspecificforan\negg-adaptedvaccinestrain.Nat.Med.22,1465\u20131469(2016).\n25. Skowronski,D.M.etal.Low2012-13influenzavaccineeffectivenessassociated\nwith mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in\ncirculatingviruses. PLo SONE9, e 92153(2014).\n26. Zost, S. J. etal. Contemporary H3N2influenzaviruseshaveaglycosylationsite\nthataltersbindingofantibodieselicitedbyegg-adaptedvaccinestrains.Proc.\nNatl Acad. Sci. USA114,12578\u201312583(2017).\n27. Flannery, B. et al. Interim estimates of 2016-17 seasonal influenza vaccine\neffectiveness-United States, February 2017. MMWRMorb. Mortal. Wkly Rep.66,\n167\u2013171(2017).\n28. Shu, Y.&Mc Cauley, J. GISAID: Globalinitiativeonsharingallinfluenzadata-from\nvisiontoreality. Eurosurveillance: bulletin Europeensurlesmaladiestransmis-\nsibles = European communicable disease bulletin 22, https://doi.org/10.2807/\n1560-7917.Es.2017.22.13.30494(2017).\n29. Song,L.etal.Efficaciousrecombinantinfluenzavaccinesproducedbyhighyield\nbacterial expression: a solution to global pandemic and seasonal needs. PLo S\nONE3,e2257(2008).\n30. Tussey, L. et al. Phase 1 safety and immunogenicity study of a quadrivalent\nseasonal flu vaccine comprising recombinant hemagglutinin-flagellin fusion\nproteins. Open Forum Infect. Dis.3, ofw 015(2016).\n31. Aguilar-Yanez, J. M. et al. An influenza A/H1N1/2009 hemagglutinin vaccine\nproducedin Escherichiacoli. PLo SONE5, e 11694(2010).\n32. Saczynska, V.Influenzavirus hemagglutinin asavaccine antigen produced in\nbacteria. Acta Biochim Pol.61,561\u2013572(2014).\n33. Davis, A. R. et al. Immune response to human influenza virus hemagglutinin\nexpressedin Escherichiacoli. Gene 21,273\u2013284(1983).\n34. Rosales-Mendoza,S.etal.Whatdoesplant-basedvaccinetechnologyoffertothe\nfightagainst COVID-19? Vaccines 8,183(2020).\n35. Pillet,S.etal.Aplant-derivedquadrivalentviruslikeparticleinfluenzavaccine"
      },
      {
        "type": "list",
        "bbox": [
          51.437180786132814,
          63.77546447753906,
          467.70644531249997,
          730.83779296875
        ],
        "confidence": 0.6247051358222961,
        "original_box": {
          "type": "List",
          "bbox": [
            51.437180786132814,
            63.77546447753906,
            467.70644531249997,
            730.83779296875
          ],
          "confidence": 0.6247051358222961
        },
        "center_x": 259.5718130493164,
        "center_y": 397.3066287231445,
        "reading_order": 3,
        "content": "efinedbyavaccine-inducedantibody. Proc. Natl Acad. Sci. USA115,168\u2013173 ticlevaccine. Biopharm. Int 23Suppl 10,26\u201334(201\n2018). 46. Fernandes,F.etal.Insectcellsasaproductionpla\nautto, G. A., Kirchenbaum, G. A. & Ross, T. M. Towards a universal influenza particles. Expert Rev. Vaccines 12,225\u2013236(2013).\naccine:differentapproachesforonegoal.Virol.J.15,17(2018). 47. Influenza vaccine strategies for broad global acces\nachbagauer,R.etal.Achimerichemagglutinin-baseduniversalinfluenzavirus azureedge.net/media/documents/VAC_infl_publ_rpt_\naccine approach induces broad and long-lasting immunity in a randomized, 2021.\nlacebo-controlledphase Itrial. Nat. Med.27,106\u2013114(2021). 48. European Medicines Agency. Assessment report.\nrenstein,W.A.&Schaffner,W.Lessonslearned:roleofinfluenzavaccinepro- EMEA/H/C/005159/0000. Available at https://www.e\nuction,distribution,supply,anddemand\u2013whatitmeansfortheprovider.Am.J. assessment-report/supemtek-epar-public-assessment-r\ned.121,S22\u2013S27(2008). February2021.\nelberbaum, R. S. The baculovirus expression vector system: a commercial 49. Health Canada. Registerof Innovative Drugs[Updat\nanufacturingplatformforviralvaccinesandgenetherapyvectors.Biotechnol.J. from https://www.canada.ca/en/health-canada/serv\n0,702\u2013714(2015). drug-products/applications-submissions/register-inn\nox,M.M.&Hashimoto,Y.Afasttrackinfluenzavirusvaccineproducedininsect sed19April2021.\nells.J.Invertebr.Pathol.107,S31\u2013S41(2011). 50. Taubenberger, J.K.Influenzavirus hemagglutinin c\naymond, D. D. etal. Influenzaimmunizationelicitsantibodiesspecificforan laughingmatter. Proc. Natl Acad. Sci. USA95,9713\u2013\ngg-adaptedvaccinestrain.Nat.Med.22,1465\u20131469(2016). 51. Stieneke-Gr\u00f6ber,A.etal.Influenzavirushemaggluti\nkowronski,D.M.etal.Low2012-13influenzavaccineeffectivenessassociated siteisactivatedbyfurin,asubtilisin-likeendoprote\nith mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in (1992).PMC556715.\nirculatingviruses. PLo SONE9, e 92153(2014). 52. Chen, J. etal. Structureofthehemagglutininprec\nost, S. J. etal. Contemporary H3N2influenzaviruseshaveaglycosylationsite minantofinfluenzapathogenicityandtheoriginof\nhataltersbindingofantibodieselicitedbyegg-adaptedvaccinestrains.Proc. 95,409\u2013417(1998).\natl Acad. Sci. USA114,12578\u201312583(2017). 53. Luczo, J. M. etal. Molecularpathogenesisof H5hig\nlannery, B. et al. Interim estimates of 2016-17 seasonal influenza vaccine enza: the role of the haemagglutinin cleavage sit\nffectiveness-United States, February 2017. MMWRMorb. Mortal. Wkly Rep.66, 406\u2013430(2015).\n67\u2013171(2017). 54. Boonstra, S. et al. Hemagglutinin-mediated mem\nhu, Y.&Mc Cauley, J. GISAID: Globalinitiativeonsharingallinfluenzadata-from perspective. Annu Rev. Biophys.47,153\u2013173(2018).\nisiontoreality. Eurosurveillance: bulletin Europeensurlesmaladiestransmis- 55. Mc Craw, D. M., Gallagher, J. R.&Harris, A. K. Characte\nibles = European communicable disease bulletin 22, https://doi.org/10.2807/ hemagglutinin complexes by cryo-electron micros\n560-7917.Es.2017.22.13.30494(2017). revealsstructuralpolymorphisms.Clin.Vaccin.Immu\nong,L.etal.Efficaciousrecombinantinfluenzavaccinesproducedbyhighyield 56. Kost,T.A.&Condreay,J.P.Recombinantbaculovirus\nacterial expression: a solution to global pandemic and seasonal needs. PLo S insectandmammaliancells. Curr. Opin. Biotechnol.\nNE3,e2257(2008). 57. Webster,R.G.,Brown,L.E.&Jackson,D.C.Change\nussey, L. et al. Phase 1 safety and immunogenicity study of a quadrivalent hemagglutininmoleculeof H3influenzavirusatacidi\neasonal flu vaccine comprising recombinant hemagglutinin-flagellin fusion (1983).\nroteins. Open Forum Infect. Dis.3, ofw 015(2016). 58. Lee, P. S.&Wilson, I. A. Structuralcharacterizationof\nguilar-Yanez, J. M. et al. An influenza A/H1N1/2009 hemagglutinin vaccine broadly cross-reactive antibodies. Curr. Top. Microbi\nroducedin Escherichiacoli. PLo SONE5, e 11694(2010). (2015).\naczynska, V. Influenzavirus hemagglutinin asavaccine antigen produced in 59. Turner, H. L. etal. Potentanti-influenza H7humanm\nacteria. Acta Biochim Pol.61,561\u2013572(2014). separation of hemagglutinin receptor-binding hea\navis, A. R. et al. Immune response to human influenza virus hemagglutinin e3000139(2019).\nxpressedin Escherichiacoli. Gene 21,273\u2013284(1983). 60. Khurana, S. etal. Repeatvaccinationreducesantibo\nosales-Mendoza,S.etal.Whatdoesplant-basedvaccinetechnologyoffertothe differentinfluenzavaccineplatformsinhumans.Nat\nghtagainst COVID-19? Vaccines 8,183(2020). 61. Ekiert, D. C. et al. Antibody recognition of a highl\nillet,S.etal.Aplant-derivedquadrivalentviruslikeparticleinfluenzavaccine epitope.Science324,246\u2013251(2009).\nnduces cross-reactive antibody and T cell response in healthy adults. Clin. 62. Kallewaard,N.L.etal.Structureandfunctionanalysis\nmmunol.168,72\u201387(2016). allinfluenza Asubtypes. Cell 166,596\u2013608(2016).\nillet,S.etal.Immunogenicityandsafetyofaquadrivalentplant-derivedvirus 63. Benhaim, M. A. etal. Structural monitoring of a tr\nikeparticleinfluenzavaccinecandidate-tworandomized Phase IIclinicaltrialsin hemagglutininfusionmachineryoninfluenzavirions.\n8to 49and>/=50yearsoldadults. PLo SONE14, e 0216533(2019). 64. Portnoff, A. D. etal. Influenzahemagglutininnanopa\nard, B. J. etal. Efficacy, immunogenicity, andsafetyofaplant-derived, quad- neutralizingantibodiesagainststructurallydistinctdo\nivalent, virus-like particle influenza vaccine in adults (18-64 years) and older 8,99(2020).\ndults (>/=65 years): two multicentre, randomised phase 3 trials. Lancet 396, 65. Richards, K. A. etal. Recombinant HA-basedvaccine\n491\u20131503(2020). unit vaccines in elicitation of influenza-specific C\non, S. Y. et al. Characterization of the innate stimulatory capacity of plant- dependentantibodyresponsesinhumans.NPJVacc\nerived virus-like particles bearing influenza hemagglutinin. Vaccine 36, 66. Tay,T.etal.Investigationintoalternativetestingmet\n028\u20138038(2018). tionofinfluenzavirusvaccine. Hum. Vaccines Immun\nandey,A.etal.Impactofpreexistingadenovirusvectorimmunityonimmu- 67. Gallagher, J. R. et al. Characterization of hemagglu\nogenicityandprotectionconferredwithanadenovirus-based H5N1influenza virus and within vaccines using electron microsco\naccine. PLo SONE7, e 33428\u2013e 33428(2012). 10.3390/vaccines 6020031(2018).\nayedahmed, E. E. etal. Adenoviral vector-based vaccine platforms for devel- 68. Public Health Agencyof Canada. Oculo-respiratorysy\npingthenextgenerationofinfluenzavaccines.Vaccines8,574(2020). vaccination:reviewofpost-marketing surveillance t\niang, K. et al. Progress on adenovirus-vectored universal influenza vaccines. sonsin Canada. Can. Commun. Dis. Rep.31,217\u201322\num. Vaccin Immunother.11,1209\u20131222(2015). 69. Choudhri, Y.&Walop, W. Influenzavaccine-associate\nhen,J.R.etal.Betterinfluenzavaccines:anindustryperspective.J.Biomed.Sci. passive surveillance, Canada 2001-2002. Can. Com\n7,33(2020). (2002).\neport to the president on reengeneering the influenza vaccine production 70. Babiuk, S. etal. Aggregatecontentinfluencesthe T\nnterprisetomeetthechallengesofpandemicinfluenza.Availableathttps:// influenzavaccine:evidencefromamousemodel.J.M\nbamawhitehouse.archives.gov/sites/default/files/microsites/ostp/PCAST- 71. Wei,C.J.etal.Cross-neutralizationof1918and20\nnfluenza-Vaccinology-Report. pdf. Accessed August 2021. glycansinviralevolutionandvaccinedesign. Sci. Tr\n\u00f3pez-Mac\u00edas,C.etal.Safetyandimmunogenicityofavirus-likeparticlepan- 72. An, Y. et al. N-glycosylation of seasonal influenz\nemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo- implicationforpotencytestingandimmuneproces\nontrolledtrialofadultsin Mexico. Vaccine 29,7826\u20137834(2011). 10.1128/JVI.01693-18(2019)."
      },
      {
        "type": "list",
        "bbox": [
          299.167734375,
          308.5583862304687,
          549.54439453125,
          714.571435546875
        ],
        "confidence": 0.7934908866882324,
        "original_box": {
          "type": "List",
          "bbox": [
            299.167734375,
            308.5583862304687,
            549.54439453125,
            714.571435546875
          ],
          "confidence": 0.7934908866882324
        },
        "center_x": 424.356064453125,
        "center_y": 511.5649108886719,
        "reading_order": 4,
        "content": "55. Mc Craw, D. M., Gallagher, J. R.&Harris, A. K. Characterizationofinfluenzavaccine\nhemagglutinin complexes by cryo-electron microscopy and image analyses\nrevealsstructuralpolymorphisms.Clin.Vaccin.Immunol.23,483\u2013495(2016).\n56. Kost,T.A.&Condreay,J.P.Recombinantbaculovirusesasexpressionvectorsfor\ninsectandmammaliancells.Curr.Opin.Biotechnol.10,428\u2013433(1999).\n57. Webster,R.G.,Brown,L.E.&Jackson,D.C.Changesintheantigenicityofthe\nhemagglutininmoleculeof H3influenzavirusatacidicp H. Virology 126,587\u2013599\n(1983).\n58. Lee,P.S.&Wilson,I.A.Structuralcharacterizationofviralepitopesrecognizedby\nbroadly cross-reactive antibodies. Curr. Top. Microbiol. Immunol. 386, 323\u2013341\n(2015).\n59. Turner, H. L. etal. Potentanti-influenza H7humanmonoclonalantibodyinduces\nseparation of hemagglutinin receptor-binding head domains. PLo S Biol. 17,\ne3000139(2019).\n60. Khurana,S.etal.Repeatvaccinationreducesantibodyaffinitymaturationacross\ndifferentinfluenzavaccineplatformsinhumans.Nat.Commun.10,3338(2019).\n61. Ekiert, D. C. et al. Antibody recognition of a highly conserved influenza virus\nepitope.Science324,246\u2013251(2009).\n62. Kallewaard,N.L.etal.Structureandfunctionanalysisofanantibodyrecognizing\nallinfluenza Asubtypes. Cell 166,596\u2013608(2016).\n63. Benhaim, M. A. etal. Structural monitoring of a transient intermediate in the\nhemagglutininfusionmachineryoninfluenzavirions.Sci.Adv.6,eaaz8822(2020).\n64. Portnoff,A.D.etal.Influenzahemagglutininnanoparticlevaccineelicitsbroadly\nneutralizingantibodiesagainststructurallydistinctdomainsof H3N2HA. Vaccines\n8,99(2020).\n65. Richards, K. A. etal. Recombinant HA-basedvaccineoutperformssplitandsub-\nunit vaccines in elicitation of influenza-specific CD4 T cells and CD4 T cell-\ndependentantibodyresponsesinhumans.NPJVaccines5,77(2020).\n66. Tay,T.etal.Investigationintoalternativetestingmethodologiesforcharacteriza-\ntionofinfluenzavirusvaccine. Hum. Vaccines Immunother.11,1673\u20131684(2015).\n67. Gallagher, J. R. et al. Characterization of hemagglutinin antigens on influenza\nvirus and within vaccines using electron microscopy. Vaccines https://doi.org/\n10.3390/vaccines6020031(2018).\n68. Public Health Agencyof Canada. Oculo-respiratorysyndromefollowinginfluenza\nvaccination:reviewofpost-marketing surveillance throughfourinfluenza sea-\nsonsin Canada. Can. Commun. Dis. Rep.31,217\u2013225(2005).\n69. Choudhri,Y.&Walop,W.Influenzavaccine-associatedadverseevents:resultsof\npassive surveillance, Canada 2001-2002. Can. Commun. Dis. Rep. 28, 189\u2013196\n(2002).\n70. Babiuk, S. etal. Aggregatecontentinfluencesthe Th 1/Th 2immuneresponseto\ninfluenzavaccine:evidencefromamousemodel.J.Med.Virol.72,138\u2013142(2004).\n71. Wei,C.J.etal.Cross-neutralizationof1918and2009influenzaviruses:roleof\nglycansinviralevolutionandvaccinedesign.Sci.Transl.Med.2,24ra21(2010).\n72. An, Y. et al. N-glycosylation of seasonal influenza vaccine hemagglutinins:\nimplicationforpotencytestingandimmuneprocessing.JVirol.https://doi.org/"
      },
      {
        "type": "list",
        "bbox": [
          299.43529541015624,
          64.42852478027343,
          553.8532763671875,
          532.3088232421875
        ],
        "confidence": 0.8876444697380066,
        "original_box": {
          "type": "List",
          "bbox": [
            299.43529541015624,
            64.42852478027343,
            553.8532763671875,
            532.3088232421875
          ],
          "confidence": 0.8876444697380066
        },
        "center_x": 426.6442858886719,
        "center_y": 298.36867401123044,
        "reading_order": 5,
        "content": "ticlevaccine.Biopharm.Int23Suppl10,26\u201334(2010).\n46. Fernandes,F.etal.Insectcellsasaproductionplatformofcomplexvirus-like\nparticles. Expert Rev. Vaccines 12,225\u2013236(2013).\n47. Influenza vaccine strategies for broad global access. Available at https://path.\nazureedge.net/media/documents/VAC_infl_publ_rpt_10-07.pdf. Accessed August\n2021.\n48. European Medicines Agency. Assessment report. Supemtek. Procedure No.\nEMEA/H/C/005159/0000. Available at https://www.ema.europa.eu/en/documents/\nassessment-report/supemtek-epar-public-assessment-report_en.pdf. Accessed 17\nFebruary2021.\n49. Health Canada. Registerof Innovative Drugs[Updated 15April 2021]. Available\nfrom https://www.canada.ca/en/health-canada/services/drugs-health-products/\ndrug-products/applications-submissions/register-innovative-drugs.html. Acces-\nsed19April2021.\n50. Taubenberger, J. K. Influenzavirus hemagglutinin cleavageinto HA1, HA2: no\nlaughingmatter. Proc. Natl Acad. Sci. USA95,9713\u20139715(1998).\n51. Stieneke-Gr\u00f6ber,A.etal.Influenzavirushemagglutininwithmultibasiccleavage\nsiteisactivatedbyfurin,asubtilisin-likeendoprotease.EMBOJ.11,2407\u20132414\n(1992).PMC556715.\n52. Chen,J.etal.Structureofthehemagglutininprecursorcleavagesite,adeter-\nminantofinfluenzapathogenicityandtheoriginofthelabileconformation.Cell\n95,409\u2013417(1998).\n53. Luczo, J. M. etal. Molecularpathogenesisof H5highlypathogenicavianinflu-\nenza: the role of the haemagglutinin cleavage site motif. Rev. Med Virol. 25,\n406\u2013430(2015).\n54. Boonstra, S. et al. Hemagglutinin-mediated membrane fusion: a biophysical\nperspective. Annu Rev. Biophys.47,153\u2013173(2018).\n55. Mc Craw, D. M., Gallagher, J. R.&Harris, A. K. Characterizationofinfluenzavaccine\nhemagglutinin complexes by cryo-electron microscopy and image analyses\nrevealsstructuralpolymorphisms.Clin.Vaccin.Immunol.23,483\u2013495(2016).\n56. Kost,T.A.&Condreay,J.P.Recombinantbaculovirusesasexpressionvectorsfor\ninsectandmammaliancells.Curr.Opin.Biotechnol.10,428\u2013433(1999).\n57. Webster,R.G.,Brown,L.E.&Jackson,D.C.Changesintheantigenicityofthe\nhemagglutininmoleculeof H3influenzavirusatacidicp H. Virology 126,587\u2013599\n(1983).\n58. Lee,P.S.&Wilson,I.A.Structuralcharacterizationofviralepitopesrecognizedby\nbroadly cross-reactive antibodies. Curr. Top. Microbiol. Immunol. 386, 323\u2013341\n(2015).\n59. Turner, H. L. etal. Potentanti-influenza H7humanmonoclonalantibodyinduces\nseparation of hemagglutinin receptor-binding head domains. PLo S Biol. 17,\ne3000139(2019).\n60. Khurana,S.etal.Repeatvaccinationreducesantibodyaffinitymaturationacross\ndifferentinfluenzavaccineplatformsinhumans.Nat.Commun.10,3338(2019).\n61. Ekiert, D. C. et al. Antibody recognition of a highly conserved influenza virus\nepitope.Science324,246\u2013251(2009).\n62. Kallewaard,N.L.etal.Structureandfunctionanalysisofanantibodyrecognizing\nallinfluenza Asubtypes. Cell 166,596\u2013608(2016).\n63. Benhaim, M. A. etal. Structural monitoring of a transient intermediate in the\nhemagglutininfusionmachineryoninfluenzavirions.Sci.Adv.6,eaaz8822(2020).\n64. Portnoff,A.D.etal.Influenzahemagglutininnanoparticlevaccineelicitsbroadly\nneutralizingantibodiesagainststructurallydistinctdomainsof H3N2HA. Vaccines\n8,99(2020)."
      }
    ]
  },
  {
    "page_num": 8,
    "page_width": 595.276,
    "page_height": 790.866,
    "ordered_elements": [
      {
        "type": "text",
        "bbox": [
          48.02065246582031,
          337.8085400390625,
          291.84888427734376,
          362.9873583984375
        ],
        "confidence": 0.5422690510749817,
        "original_box": {
          "type": "Text",
          "bbox": [
            48.02065246582031,
            337.8085400390625,
            291.84888427734376,
            362.9873583984375
          ],
          "confidence": 0.5422690510749817
        },
        "center_x": 169.93476837158204,
        "center_y": 350.39794921875,
        "reading_order": 1,
        "content": "4. Centers for Disease Control Prevention. Estimates of deaths associated with\nseasonalinfluenza\u2014United States,1976-2007. MMWRMorb. Mortal. Wkly Rep.\n59,1057\u20131062(2010)."
      },
      {
        "type": "list",
        "bbox": [
          43.23636474609375,
          51.78988037109375,
          290.74792236328125,
          553.52126953125
        ],
        "confidence": 0.9650207757949829,
        "original_box": {
          "type": "List",
          "bbox": [
            43.23636474609375,
            51.78988037109375,
            290.74792236328125,
            553.52126953125
          ],
          "confidence": 0.9650207757949829
        },
        "center_x": 166.9921435546875,
        "center_y": 302.6555749511719,
        "reading_order": 2,
        "content": "73. Schwarzer,J.etal.Glycananalysisincellculture-basedinfluenzavaccinepro\nduction:influenceofhostcelllineandvirusstrainontheglycosylationpatterno\nviralhemagglutinin.Vaccine27,4325\u20134336(2009).\n74. Chung, C. Y. etal. Snap Shot: N-glycosylationprocessingpathwaysacrossking\ndoms.Cell171,258\u2013258.e251(2017).\n75. Wang,C.C.etal.Glycansoninfluenzahemagglutininaffectreceptorbindingan\nimmuneresponse. Proc. Natl Acad. Sci. USA106,18137\u201318142(2009).\n76. Chen,J.R.etal.Vaccinationofmonoglycosylatedhemagglutinininducescross\nstrainprotectionagainstinfluenzavirusinfections. Proc. Natl Acad. Sci. USA111\n2476\u20132481(2014).\n77. Henry,C.etal.Monoclonalantibodyresponsesafterrecombinanthemagglutini\nvaccineversussubunitinactivatedinfluenzavirusvaccine:acomparativestudy.J\nVirol.https://doi.org/10.1128/JVI.01150-19(2019).\n78. Nachbagauer,R.etal.Agedependenceandisotypespecificityofinfluenzaviru\nhemagglutininstalk-reactiveantibodiesinhumans. m Bio 7, e 01996\u201301915(2016)\n79. Reichert,T.etal.Doesglycosylationasamodifieroforiginalantigenicsinexplai\nthecaseagedistributionandunusualtoxicityinpandemicnovel H1N1influenza\nBMCInfect.Dis.10,5(2010).\n80. Wang,K.etal.Expressionandpurificationofaninfluenzahemagglutinin\u2013on\nstep closer to a recombinant protein-based influenza vaccine. Vaccine 24\n2176\u20132185(2006).\n81. Treanor,J.J.etal.Protectiveefficacyofatrivalentrecombinanthemagglutini\nproteinvaccine (Flu Blok(R)) against influenzain healthyadults: a randomized\nplacebo-controlledtrial.Vaccine29,7733\u20137739(2011).\n82. Belongia,E.A.etal.Clinicaltrialtoassessimmunogenicityofhigh-dose,adju\nvanted, andrecombinantinfluenzavaccinesagainstcell-grown A(H3N2)viruse\ninadults65to74years,2017-2018.Vaccine38,3121\u20133128(2020).\n83. Shinde,V.etal.Inductionofcross-reactivehemagglutinationinhibitingantibod\nand polyfunctional CD4+ T-cell responses by a recombinant matrix-M\nadjuvanted hemagglutinin nanoparticle influenza vaccine. Clin. Infect. Dis\nhttps://doi.org/10.1093/cid/ciaa1673(2020).\n84. Centers for Disease Control Prevention. Estimates of deaths associated wit\nseasonalinfluenza\u2014United States,1976-2007. MMWRMorb. Mortal. Wkly Rep\n59,1057\u20131062(2010).\n85. Goldstein, M. A. & Tauraso, N. M. Effect of formalin, beta-propiolactone, mer\nthiolate,andultravioletlightuponinfluenzavirusinfectivitychickencellagglu\ntination,hemagglutination,andantigenicity.Appl.Microbiol.19,290\u2013294(1970)\n86. Uittenbogaard, J. P., Zomer, B., Hoogerhout, P. & Metz, B. Reactions of beta\npropiolactone with nucleobase analogues, nucleosides, and peptides: implica\ntionsfortheinactivationofviruses.J.Biol.Chem.286,36198\u201336214(2011).\n87. She,Y.M.etal.Surfacemodificationsofinfluenzaproteinsuponvirusinactiva\ntionby\u03b2-propiolactone.Proteomics13,3537\u20133547(2013).\n88. Herrera-Rodriguez, J. et al. Inactivated or damaged? Comparing the effect o\ninactivationmethodsoninfluenzavirionstooptimize.Vaccin.Prod.Vaccin.37\n1630\u20131637(2019).\n89. Li,J.T.,Rank,M.A.,Squillace,D.L.&Kita,H.Ovalbumincontentofinfluenz\nvaccines. J. Allergy Clin. Immunol.125,1412\u20131413(2010). authorreply 1413-1414\n90. Garcia-Canas, V. et al. Selective and quantitative detection of influenza viru\nproteinsincommercialvaccinesusingtwo-dimensionalhigh-performanceliqui\nchromatographyandfluorescencedetection.Anal.Chem.79,3164\u20133172(2007)\n91. Garcia-Canas,V.,Lorbetskie,B.&Girard,M.Rapidandselectivecharacterizationo\ninfluenzavirusconstituentsinmonovalentandmultivalentpreparationsusin\nnon-porousreversed-phasehighperformanceliquidchromatographycolumns.J\nChromatogr.A1123,225\u2013232(2006)."
      },
      {
        "type": "title",
        "bbox": [
          311.48962646484375,
          536.7035302734375,
          374.589580078125,
          546.1002685546874
        ],
        "confidence": 0.5391474366188049,
        "original_box": {
          "type": "Title",
          "bbox": [
            311.48962646484375,
            536.7035302734375,
            374.589580078125,
            546.1002685546874
          ],
          "confidence": 0.5391474366188049
        },
        "center_x": 343.03960327148434,
        "center_y": 541.4018994140624,
        "reading_order": 3,
        "content": "\u00a9The Author(s)2021"
      },
      {
        "type": "title",
        "bbox": [
          310.2955224609375,
          310.4438818359375,
          426.0488818359375,
          321.2746435546875
        ],
        "confidence": 0.9886133670806885,
        "original_box": {
          "type": "Title",
          "bbox": [
            310.2955224609375,
            310.4438818359375,
            426.0488818359375,
            321.2746435546875
          ],
          "confidence": 0.9886133670806885
        },
        "center_x": 368.17220214843746,
        "center_y": 315.8592626953125,
        "reading_order": 4,
        "content": "ADDITIONAL INFORMATION"
      },
      {
        "type": "title",
        "bbox": [
          310.2853051757812,
          261.522861328125,
          407.6010791015625,
          272.5695703125
        ],
        "confidence": 0.9792298674583435,
        "original_box": {
          "type": "Title",
          "bbox": [
            310.2853051757812,
            261.522861328125,
            407.6010791015625,
            272.5695703125
          ],
          "confidence": 0.9792298674583435
        },
        "center_x": 358.94319213867186,
        "center_y": 267.04621582031245,
        "reading_order": 5,
        "content": "COMPETINGINTERESTS"
      },
      {
        "type": "title",
        "bbox": [
          310.1530517578125,
          195.25493408203124,
          416.3020751953125,
          206.31254150390623
        ],
        "confidence": 0.9977368116378784,
        "original_box": {
          "type": "Title",
          "bbox": [
            310.1530517578125,
            195.25493408203124,
            416.3020751953125,
            206.31254150390623
          ],
          "confidence": 0.9977368116378784
        },
        "center_x": 363.2275634765625,
        "center_y": 200.78373779296874,
        "reading_order": 6,
        "content": "AUTHORCONTRIBUTIONS"
      },
      {
        "type": "title",
        "bbox": [
          311.18690917968746,
          121.07965209960938,
          403.5185595703125,
          131.647939453125
        ],
        "confidence": 0.993751585483551,
        "original_box": {
          "type": "Title",
          "bbox": [
            311.18690917968746,
            121.07965209960938,
            403.5185595703125,
            131.647939453125
          ],
          "confidence": 0.993751585483551
        },
        "center_x": 357.35273437499995,
        "center_y": 126.36379577636718,
        "reading_order": 7,
        "content": "ACKNOWLEDGEMENTS"
      },
      {
        "type": "text",
        "bbox": [
          312.8496459960937,
          425.94319335937496,
          559.4053271484374,
          515.6194921875
        ],
        "confidence": 0.9889256358146667,
        "original_box": {
          "type": "Text",
          "bbox": [
            312.8496459960937,
            425.94319335937496,
            559.4053271484374,
            515.6194921875
          ],
          "confidence": 0.9889256358146667
        },
        "center_x": 436.1274865722656,
        "center_y": 470.7813427734375,
        "reading_order": 8,
        "content": "Attribution 4.0 International License, which permits use, sharing,\nadaptation,distributionandreproductioninanymediumorformat,aslongasyougive\nappropriatecredittotheoriginalauthor(s)andthesource, providealinktothe Creative\nCommonslicense,andindicateifchangesweremade.Theimagesorotherthirdparty\nmaterialinthisarticleareincludedinthearticle\u2019s Creative Commonslicense, unless\nindicatedotherwiseinacreditlinetothematerial.Ifmaterialisnotincludedinthe\narticle\u2019s Creative Commonslicenseandyourintendeduseisnotpermittedbystatutory\nregulationorexceedsthepermitteduse,youwillneedtoobtainpermissiondirectly\nfromthecopyrightholder.Toviewacopyofthislicense,visithttp://creativecommons."
      },
      {
        "type": "text",
        "bbox": [
          311.91277587890625,
          377.5162060546875,
          560.95435546875,
          393.761689453125
        ],
        "confidence": 0.9508141279220581,
        "original_box": {
          "type": "Text",
          "bbox": [
            311.91277587890625,
            377.5162060546875,
            560.95435546875,
            393.761689453125
          ],
          "confidence": 0.9508141279220581
        },
        "center_x": 436.4335656738281,
        "center_y": 385.6389477539062,
        "reading_order": 9,
        "content": "Publisher\u2019snote Springer Natureremainsneutralwithregardtojurisdictionalclaims\ninpublishedmapsandinstitutionalaffiliations."
      },
      {
        "type": "text",
        "bbox": [
          310.23169189453125,
          350.74430419921873,
          559.8204345703125,
          368.11878662109376
        ],
        "confidence": 0.7079799771308899,
        "original_box": {
          "type": "Text",
          "bbox": [
            310.23169189453125,
            350.74430419921873,
            559.8204345703125,
            368.11878662109376
          ],
          "confidence": 0.7079799771308899
        },
        "center_x": 435.02606323242185,
        "center_y": 359.4315454101562,
        "reading_order": 10,
        "content": "Reprints and permission information is available at http://www.nature.com/\nreprints"
      },
      {
        "type": "text",
        "bbox": [
          310.285634765625,
          350.49781494140626,
          559.1132666015625,
          359.39256591796874
        ],
        "confidence": 0.5321225523948669,
        "original_box": {
          "type": "Text",
          "bbox": [
            310.285634765625,
            350.49781494140626,
            559.1132666015625,
            359.39256591796874
          ],
          "confidence": 0.5321225523948669
        },
        "center_x": 434.69945068359374,
        "center_y": 354.9451904296875,
        "reading_order": 11,
        "content": "Reprints and permission information is available at http://www.nature.com/"
      },
      {
        "type": "text",
        "bbox": [
          309.8444677734375,
          323.2904150390625,
          563.9789355468749,
          341.01635009765624
        ],
        "confidence": 0.9698144793510437,
        "original_box": {
          "type": "Text",
          "bbox": [
            309.8444677734375,
            323.2904150390625,
            563.9789355468749,
            341.01635009765624
          ],
          "confidence": 0.9698144793510437
        },
        "center_x": 436.9117016601562,
        "center_y": 332.15338256835935,
        "reading_order": 12,
        "content": "Correspondence and requests for materials should be addressed to Arun B.\nArunachalam."
      },
      {
        "type": "text",
        "bbox": [
          311.0895263671875,
          274.89796875,
          557.7861181640625,
          292.10737060546876
        ],
        "confidence": 0.9914585947990417,
        "original_box": {
          "type": "Text",
          "bbox": [
            311.0895263671875,
            274.89796875,
            557.7861181640625,
            292.10737060546876
          ],
          "confidence": 0.9914585947990417
        },
        "center_x": 434.43782226562496,
        "center_y": 283.5026696777344,
        "reading_order": 13,
        "content": "All authors are employees of Sanofi Pasteur and may hold shares and/or stock\noptionsinthecompany."
      },
      {
        "type": "text",
        "bbox": [
          311.89025390625,
          209.026669921875,
          558.2255712890625,
          244.46414794921873
        ],
        "confidence": 0.9942757487297058,
        "original_box": {
          "type": "Text",
          "bbox": [
            311.89025390625,
            209.026669921875,
            558.2255712890625,
            244.46414794921873
          ],
          "confidence": 0.9942757487297058
        },
        "center_x": 435.05791259765624,
        "center_y": 226.74540893554686,
        "reading_order": 14,
        "content": "A. A. conceptualised, designed, andpreparedtheoriginaldraftand Fig.2; D. R. and P. P\nexpandedtheclinicalandtheregulatorysectionsrespectively;allauthorsreviewed\nandcommentedonthemanuscriptatallstages,approvedthefinaldraft,andremain\naccountablefortheaccuracyandintegrityofthework."
      },
      {
        "type": "text",
        "bbox": [
          312.4850537109375,
          134.10763549804688,
          558.5466796874999,
          177.60253051757812
        ],
        "confidence": 0.9962131977081299,
        "original_box": {
          "type": "Text",
          "bbox": [
            312.4850537109375,
            134.10763549804688,
            558.5466796874999,
            177.60253051757812
          ],
          "confidence": 0.9962131977081299
        },
        "center_x": 435.5158666992187,
        "center_y": 155.85508300781248,
        "reading_order": 15,
        "content": "Editorialassistancewiththepreparationofthemanuscriptwasprovidedby Juliette\nGray, in Science Communications, Springer Healthcare Ltd, UKandwasfundedby\nSanofi Pasteur. Graphic design support provided by Naveen Kandibanda (Sanofi).\nTheauthorsalsothank Kathryn Bonaparte(Sanofi Pasteur)foreditorialassistanceand\nmanuscriptcoordination."
      },
      {
        "type": "list",
        "bbox": [
          309.44729003906247,
          59.36978759765625,
          560.5887744140625,
          104.46802734375
        ],
        "confidence": 0.737604558467865,
        "original_box": {
          "type": "List",
          "bbox": [
            309.44729003906247,
            59.36978759765625,
            560.5887744140625,
            104.46802734375
          ],
          "confidence": 0.737604558467865
        },
        "center_x": 435.01803222656247,
        "center_y": 81.91890747070312,
        "reading_order": 16,
        "content": "92. Lin,Y.T.etal.Correlationofovalbuminofeggwhitecomponentswithallergic\ndiseasesinchildren.J.Microbiol.Immunol.Infect.49,112\u2013118(2016).\n93. Vaccineexcipientsummary.Availableathttps://www.cdc.gov/vaccines/pubs/\npinkbook/downloads/appendices/b/excipient-table-2.pdf. Accessed August\n2021."
      },
      {
        "type": "text",
        "bbox": [
          308.3991064453125,
          58.297961425781246,
          562.49208984375,
          104.4760693359375
        ],
        "confidence": 0.535094141960144,
        "original_box": {
          "type": "Text",
          "bbox": [
            308.3991064453125,
            58.297961425781246,
            562.49208984375,
            104.4760693359375
          ],
          "confidence": 0.535094141960144
        },
        "center_x": 435.44559814453123,
        "center_y": 81.38701538085937,
        "reading_order": 17,
        "content": "92. Lin,Y.T.etal.Correlationofovalbuminofeggwhitecomponentswithallergic\ndiseasesinchildren.J.Microbiol.Immunol.Infect.49,112\u2013118(2016).\n93. Vaccineexcipientsummary.Availableathttps://www.cdc.gov/vaccines/pubs/\npinkbook/downloads/appendices/b/excipient-table-2.pdf. Accessed August\n2021."
      }
    ]
  }
]